risedronic acid has been researched along with Age-Related Osteoporosis in 390 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of once-weekly risedronate with and without cholecalciferol in bone mineral density (BMD) in Korean patients with osteoporosis was compared." | 9.30 | Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis. ( Chang, JS; Choi, H; Chung, HY; Kang, MI; Kim, IJ; Koh, JM; Moon, SH; Park, HM; Park, SY; Park, YS; Rhee, Y; Shin, CS; Won, YY; Yoon, HK; Yoon, TR; Yun, SC, 2019) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 9.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 9.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| " We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis." | 9.14 | Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. ( Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN, 2009) |
| " The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment." | 9.14 | Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. ( Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P, 2010) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 9.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 9.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan." | 9.10 | A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 8.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 8.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "e risedronate and alendronate in the treatment of osteoporosis." | 7.91 | Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. ( Cui, P; Jia, B; Kong, F; Wang, D, 2019) |
| " In this study, we explored the prospective use of risedronate functionalised chitosan nanoparticle (RISCN) for management and treatment of osteoporosis." | 7.91 | Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies. ( Anbu, J; Mukherjee, D; Murahari, M; Santhosh, S; Teja, BV, 2019) |
| "In this study, we investigated the potential of thiolated chitosan-based mucoadhesive film, loaded with risedronate sodium in the treatment of osteoporosis." | 7.88 | Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. ( Anbu, J; Azamthulla, M; Banala, VT; Mukherjee, D; Ramachandra, SG; Srinivasan, B, 2018) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 7.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen." | 6.82 | Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). ( Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T, 2016) |
| "Osteoporosis is a fatal bone-wearing malady and a substantial reason behind the impermanence of human life and economic burden." | 5.91 | Dissolving microneedle transdermal patch loaded with Risedronate sodium and Ursolic acid bipartite nanotransfersomes to combat osteoporosis: Optimization, characterization, in vitro and ex vivo assessment. ( Ali, A; Aqil, M; Jabi, B; Mujeeb, M; Sultana, N; Sultana, Y; Waheed, A; Yaqub Khan, M, 2023) |
| "This study assessed the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs) (bazedoxifene, raloxifene) and placebo for the treatment of osteoporosis in hormone-sensitive cancer patients receiving endocrine therapy (men with prostate cancer [MPC] on hormone ablation therapy [HAT], and women with breast cancer [WBC] on adjuvant aromatase inhibitor therapy [AAIT])." | 5.41 | The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "To assess the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW)." | 5.41 | The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | 5.36 | Intravenous zoledronic acid: what are the indications for male osteoporosis? ( Maricic, M, 2010) |
| "The efficacy of once-weekly risedronate with and without cholecalciferol in bone mineral density (BMD) in Korean patients with osteoporosis was compared." | 5.30 | Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis. ( Chang, JS; Choi, H; Chung, HY; Kang, MI; Kim, IJ; Koh, JM; Moon, SH; Park, HM; Park, SY; Park, YS; Rhee, Y; Shin, CS; Won, YY; Yoon, HK; Yoon, TR; Yun, SC, 2019) |
| " zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO)." | 5.17 | Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. ( Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G, 2013) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 5.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 5.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| " We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis." | 5.14 | Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. ( Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN, 2009) |
| " The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment." | 5.14 | Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. ( Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P, 2010) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 5.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "In a prospective, randomized controlled trial of previously untreated postmenopausal women with osteoporosis, oral BP therapy (daily doses of either 10 mg alendronate or 5 mg risedronate) in combination with calcium/vitamin D was compared to calcium/vitamin D treatment alone (control group)." | 5.12 | Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. ( Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V, 2006) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 5.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan." | 5.10 | A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002) |
| "Minodronate has better clinical efficacy in the treatment of osteoporosis than other drugs (alendronate, risedronate, raloxifene, or eldecalcitol)." | 5.05 | Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis. ( Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z, 2020) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| " In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. ( Okazaki, R, 2009) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 4.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| " Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis." | 4.83 | Bisphosphonates. ( Botsis, D; Christodoulakos, G; Lambrinoudaki, I, 2006) |
| "Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords." | 4.81 | Risedronate: a clinical review. ( Crandall, C, 2001) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 4.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long-term use of alendronate, one of the most commonly used drugs for osteoporosis currently." | 4.31 | Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. ( Chen, Y; Huang, Y; Xiao, Y, 2023) |
| "We believe that the continuous use of alendronate and risedronate for 10 years could be an option for the treatment of postmenopausal osteoporosis patients." | 3.96 | Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. ( Iba, K; Sonoda, T; Takada, J; Yamashita, T, 2020) |
| "e risedronate and alendronate in the treatment of osteoporosis." | 3.91 | Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. ( Cui, P; Jia, B; Kong, F; Wang, D, 2019) |
| " In this study, we explored the prospective use of risedronate functionalised chitosan nanoparticle (RISCN) for management and treatment of osteoporosis." | 3.91 | Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies. ( Anbu, J; Mukherjee, D; Murahari, M; Santhosh, S; Teja, BV, 2019) |
| "In this study, we investigated the potential of thiolated chitosan-based mucoadhesive film, loaded with risedronate sodium in the treatment of osteoporosis." | 3.88 | Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. ( Anbu, J; Azamthulla, M; Banala, VT; Mukherjee, D; Ramachandra, SG; Srinivasan, B, 2018) |
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| " Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8." | 3.83 | Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal. ( Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G, 2016) |
| "Little is known of the effect of alendronate and risedronate on osteoporotic fractures after discontinuation of therapy." | 3.81 | Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). ( Garellick, G; Landfeldt, E; Ström, O, 2015) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| " aestivum (200 and 400 mg/kg/day, po, for 30 days) and risedronate (20 microg/kg, sc, five times a week for 30 days) following methyl prednisolone sodium succinate (10 mg/kg, sc, thrice a week for 4 weeks) induced osteoporosis in Wistar rats showed an increase in the serum levels of bone mineral content markers, decrease in the serum and urinary levels of bone resorption markers." | 3.80 | Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. ( Abbagoni, S; Banji, D; Banji, OJ; Chiluka, VL, 2014) |
| " The objective of this study was to investigate the association between AGS and persistence with alendronate treatment of primary osteoporosis in Sweden." | 3.78 | The association between automatic generic substitution and treatment persistence with oral bisphosphonates. ( Landfeldt, E; Ström, O, 2012) |
| "Bisphosphonates (BP), especially alendronate and risedronate, are the drugs most commonly used for osteoporosis treatment, being incorporated into the skeleton where they inhibit bone resorption and are thereafter slowly released during bone turnover." | 3.77 | Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. ( Guañabens, N; Martínez-Ferrer, A; Monegal, A; Olivares, V; Peris, P; Reyes, R; Torra, M, 2011) |
| "One of the patients was treated with alendronate therapy in concern of her risk factors for osteoporosis (her previous a hysterectomy with bilateral oophorectomy) with unsubstantiated evidence of her pretreatment, bone-mineral-density measurements (BMD), for a 10-year prior episode of left prodromal thigh pain and an insufficiency fracture at 8 days post experiencing the pain." | 3.77 | Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. ( Angthong, C; Angthong, W, 2011) |
| "3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1-hydroxyethylidenebis(phosphonic acid) (risedronic acid, 2), an osteoporosis drug that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, preventing protein prenylation." | 3.76 | Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. ( Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA, 2010) |
| " Six-month-old Sprague-Dawley OVX rats (n=60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis." | 3.76 | Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. ( Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S, 2010) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 3.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "A 77-year-old man, treated with risedronic acid to prevent corticosteroid-induced osteoporosis, was admitted to hospital with acute abdominal pain." | 3.74 | [Severe oesophagus injury as a complication during treatment with risedronic acid]. ( Bijlsma, A; Blokzijl, H; Vecht, J, 2008) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| "Patients were eligible for inclusion if they had osteoporosis or osteopenia and demonstrated a decline in BMD during the preceding year while taking stable doses of alendronate or risedronate, plus supplemental calcium and vitamin D." | 3.74 | Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. ( Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S, 2008) |
| "Investigators identified a continuously benefit-eligible cohort of women from a large, geographically diverse, national managed care plan who were newly diagnosed and treated for osteoporosis with alendronate, risedronate, or raloxifene." | 3.73 | Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. ( Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA, 2006) |
| "Three simple, accurate and sensitive spectrophotometric methods are developed for the determination of some new drugs for the treatment of osteoporosis: risedronate sodium (I), alendronate sodium (II) and etidronate disodium (III)." | 3.72 | Spectrophotometric determination of some drugs for osteoporosis. ( Taha, EA; Youssef, NF, 2003) |
| " Incident of non-traumatic spine fractures and adverse events were tracked as safety endpoints." | 3.01 | Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial. ( Amasaki, Y; Atsumi, T; Fujieda, Y; Fukaya, S; Furukawa, S; Furusaki, A; Horita, T; Iwasaki, N; Kasahara, H; Katayama, K; Kato, M; Katsumata, K; Kurita, T; Matsui, K; Nishimoto, N; Oku, K; Sagawa, A; Shane, P; Takahata, M; Takeda, T; Takeuchi, K; Tanimura, K; Tsutsumi, A; Yasuda, S, 2021) |
| " The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects." | 2.90 | Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial. ( Caramori, CA; Lima, TB; Nunes, HRC; Qi, X; Romeiro, FG; Santos, LAA; Silva, GF, 2019) |
| " In addition, we looked at benefit and harm comparisons between different dosage regimens for risedronate and between risedronate and other anti-osteoporotic drugs." | 2.82 | Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. ( Hsieh, SC; Liu, W; Peterson, J; Tugwell, P; Wells, GA; Zheng, C, 2022) |
| " Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms." | 2.82 | Novel formulations of oral bisphosphonates in the treatment of osteoporosis. ( Al-Daghri, N; Bock, O; Branco, J; Bruyère, O; Casado, E; Cavalier, E; Cooper, C; Cortet, B; de Wit, M; Fuggle, N; Giusti, A; Halbout, P; Harvey, NC; Hiligsmann, M; Kanis, JA; Kaufman, JM; Kurth, A; Maggi, S; Matijevic, R; Minisola, S; Palacios, S; Radermecker, RP; Reginster, JY; Rizzoli, R; Thomasius, F; Tuzun, S; Veronese, N, 2022) |
| "Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen." | 2.82 | Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). ( Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T, 2016) |
| " Adverse event incidence was marginally higher in DL compared with non-DL (Relative risk 1." | 2.82 | Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. ( Inoue, D; Muraoka, R; Nishizawa, Y; Okazaki, R; Sugimoto, T, 2016) |
| " Bone mineral density (BMD), biochemical markers of bone metabolism, fractures, and adverse events (AEs) were evaluated." | 2.79 | Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. ( Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H, 2014) |
| " A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively)." | 2.78 | The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. ( Itoh, S; Sekino, Y; Shinomiya, K; Takeda, S, 2013) |
| "Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis." | 2.77 | Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. ( Fedorak, RN; McQueen, B; Siffledeen, J; Siminoski, K; Soo, I, 2012) |
| " The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results." | 2.77 | Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. ( Boonen, S; Eusebio, R; Lorenc, RS; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2012) |
| "Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss." | 2.76 | Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. ( Izumi, K; Kitagawa, Y; Koh, E; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K, 2011) |
| "Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis." | 2.76 | Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. ( Fujii, Y; Fujita, T; Miyauchi, A; Nakajima, M; Ohue, M; Takagi, Y, 2011) |
| "Secondary outcomes included changes in bone resorption (betaCTX) and 12-month changes in BMD." | 2.75 | Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. ( Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B, 2010) |
| "Steroid-induced osteoporosis is a serious adverse effect of this drug." | 2.75 | Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. ( Amemiya, N; Itabashi, M; Karasawa, K; Kawanishi, K; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Shimizu, A; Shiohira, S; Sugiura, H; Takei, T; Tsuchiya, K; Tsukada, M; Uchida, K, 2010) |
| "Osteoporosis is a common condition in men that can have serious clinical consequences." | 2.74 | Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2009) |
| "Male osteoporosis is increasingly recognized as a major public health issue." | 2.74 | Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. ( Boonen, S; Delmas, PD; Eusebio, R; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2009) |
| " Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose." | 2.74 | Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. ( Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009) |
| "Urinary deoxypyridinoline, a bone resorption marker, decreased by 46." | 2.73 | Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007) |
| "Proximal bone resorption around the femoral stem often has been observed after total hip arthroplasty (THA), could lead to late stem loosening." | 2.73 | Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. ( Fuji, T; Masuhara, K; Nakai, T; Seino, Y; Yamaguchi, K; Yamasaki, S, 2007) |
| "Osteoporosis is a common adverse reaction induced by glucocorticoid treatment." | 2.73 | Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. ( Ichimura, A; Iwata, H; Nakajima, T; Ochiai, H; Takagi, H; Toriyama, T; Tsuchiya, H; Yamada, S, 2007) |
| "Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture." | 2.73 | Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. ( Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K, 2007) |
| "Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after fracture among men compared with women." | 2.72 | Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2006) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients." | 2.72 | Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. ( Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H, 2006) |
| "In this multicenter, randomized, double-blind controlled trial, the efficacy and safety of once-weekly dosing with 17." | 2.72 | Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. ( Fukunaga, M; Itabashi, A; Kishimoto, H; Kushida, K; Nakamura, T; Nawata, H; Ohashi, Y; Ohta, H; Shiraki, M; Takaoka, K, 2006) |
| "To determine the clinical recommended dosage regimen of risedronate for the treatment of involutional osteoporosis in Japanese patients, dose-response relationships for the efficacy and safety of this drug were investigated using a multi-center, randomized, double-blind, parallel group comparative design with four dose levels of risedronate (placebo, 1 mg, 2." | 2.71 | A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2003) |
| " Therefore, the pharmacokinetic profile of risedronate was considered to show linearity in a dosage range of up to 20 mg." | 2.71 | Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. ( Cyong, JC; Gonsho, A; Ogura, Y; Orimo, H, 2004) |
| " Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events." | 2.69 | Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. ( Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH, 2000) |
| "The preferred treatment for osteoporosis in men is debated, and pairwise meta-analysis cannot obtain hierarchies of these treatments." | 2.52 | Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. ( Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "After patients with osteoporosis are identified, the challenge is to treat them appropriately." | 2.47 | Treatments for osteoporosis in people with a disability. ( Smith, EM, 2011) |
| "The use of endocrine therapy in breast cancer represents one of the earliest molecular targeting strategies used in cancer treatment." | 2.46 | Challenges in clinical patient management. ( Aapro, MS, 2010) |
| "Treatment with menatetrenone, risedronate or regular sunlight exposure are safe and effective in increasing bone mass and reducing the risk of hip fracture in patients with AD." | 2.46 | [Dementia and fracture]. ( Sato, Y, 2010) |
| "Male osteoporosis is an important public health issue and remains undertreated." | 2.45 | Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. ( Chen, JT; Zhong, ZM, 2009) |
| "Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts." | 2.45 | [Risedronate for treatment of osteoporosis]. ( Hagino, H, 2009) |
| " Fracture trials were initially performed with daily formulations, then bridging trials, in which the efficacy of intermittent dosing was assessed versus daily using validated surrogate endpoints for fracture." | 2.45 | Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. ( Epstein, S; Jeglitsch, M; McCloskey, E, 2009) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | 2.44 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008) |
| "5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen." | 2.44 | [Efficacy and tolerability of risedronate for the treatment of osteoporosis]. ( Kishimoto, H, 2008) |
| "They are indicated for the treatment of osteoporosis." | 2.44 | Osteochemonecrosis of jaws and bisphosphonates. ( Beirne, JC; Khosa, AD; Nayyar, MS, 2007) |
| " In placebo controlled trials it has been shown to be safe and effective in preventing fractures." | 2.44 | Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. ( Adachi, JD; Bobba, R, 2007) |
| "Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures." | 2.44 | Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. ( Iwamoto, J; Matsumoto, H; Takeda, T, 2008) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.43 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005) |
| "Clinically, osteoporosis is diagnosed using dual energy x-ray absorptiometry." | 2.43 | Microcracks in cortical bone: how do they affect bone biology? ( Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ, 2005) |
| " The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used." | 2.43 | Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006) |
| "In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate." | 2.43 | [Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005) |
| "RSD is available for the treatment of osteoporosis." | 2.42 | [Risedronate]. ( Fukunaga, M, 2003) |
| "Osteoporosis is associated with increased risk of fractures at most skeletal sites." | 2.42 | [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint]. ( Sohen, S, 2003) |
| " The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate." | 2.42 | Bisphosphonates: new indications and methods of administration. ( Reid, IR, 2003) |
| "In recent years, treatments for osteoporosis have been developing rapidly, and many of these research results have been reported." | 2.42 | [Bone quality in treatment with raroxifene ]. ( Nakamura, T, 2004) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "The diagnosis and treatment of osteoporosis is an important aspect of gynecologic training and practice." | 2.41 | Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature. ( Jennings, JC; Kauffman, RP; Overton, TH; Shiflett, M, 2001) |
| " Some bisphosphonates have been associated with upper gastrointestinal (GI) tract adverse effects." | 2.41 | Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. ( Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H, 2002) |
| "Osteoporosis is a fatal bone-wearing malady and a substantial reason behind the impermanence of human life and economic burden." | 1.91 | Dissolving microneedle transdermal patch loaded with Risedronate sodium and Ursolic acid bipartite nanotransfersomes to combat osteoporosis: Optimization, characterization, in vitro and ex vivo assessment. ( Ali, A; Aqil, M; Jabi, B; Mujeeb, M; Sultana, N; Sultana, Y; Waheed, A; Yaqub Khan, M, 2023) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| " They are associated with gastrointestinal adverse reactions the most severe being an esophageal ulcer." | 1.62 | Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients. ( Bouin, M; Nguyen, PV; Ste-Marie, LG, 2021) |
| "To develop a population pharmacokinetic model that describes the absorption and low plasma levels of risedronate in the body." | 1.62 | Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. ( Cardozo, B; Karalis, V; Karatza, E, 2021) |
| "Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects." | 1.56 | Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. ( Adib, G; Adler, RA; Åkesson, KE; Alexander, IM; Amenta, KC; Blank, RD; Brox, WT; Carmody, EE; Chapman-Novakofski, K; Clarke, BL; Cody, KM; Conley, RB; Cooper, C; Crandall, CJ; Dirschl, DR; Eagen, TJ; Elderkin, AL; Fujita, M; Greenspan, SL; Halbout, P; Hochberg, MC; Javaid, M; Jeray, KJ; Kearns, AE; Khosla, S; Kiel, DP; King, T; Koinis, TF; Koontz, JS; Kužma, M; Lindsey, C; Lorentzon, M; Lyritis, GP; Michaud, LB; Miciano, A; Morin, SN; Mujahid, N; Napoli, N; Olenginski, TP; Puzas, JE; Rizou, S; Rosen, CJ; Saag, K; Thompson, E; Tosi, LL; Tracer, H, 2020) |
| "We analyzed patients with chronic obstructive pulmonary disease whose bone mineral density were measured at least three times over three years (n = 111)." | 1.51 | Predictive and modifying factors of bone mineral density decline in patients with COPD. ( Asano, K; Betsuyaku, T; Chubachi, S; Fukunaga, K; Irie, H; Kameyama, N; Nakamura, H; Sakurai, K; Sasaki, M; Sayama, K; Tsutsumi, A, 2019) |
| " Biochemical and in-vivo pharmacokinetic studies on osteoporotic rat model treated with different formulations were performed." | 1.43 | Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. ( Ahmad, FJ; Ahmad, I; Gupta, S; Pandey, S; Rawat, P; Talegaonkar, S; Thomas, SC; Vohora, D, 2016) |
| "Osteoporosis is a major health threat nowadays." | 1.43 | Use of drugs against osteoporosis in the Baltic countries during 2010-2014. ( Kõks, S; Laius, O; Maasalu, K; Märtson, A, 2016) |
| "Despite the lack of consensus on the treatment of osteoporosis in NF1, risedronate may hold a promise as a potential therapy for osteoporosis complicating NF1." | 1.42 | Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. ( Benlidayi, IC; Kozanoglu, E; Ortac, EA, 2015) |
| "Multiple therapies are approved for the treatment of osteoporosis (OP), but many patients with osteoporosis may not initiate treatment upon osteoporosis diagnosis." | 1.40 | Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. ( Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J, 2014) |
| " Determinants associated with higher risk to non-persistence within the first year were daily dosing regimen [HR, 1." | 1.39 | Persistence with osteoporosis medication among newly-treated osteoporotic patients. ( de Boer, PT; Postma, MJ; van Boven, JF; Vegter, S, 2013) |
| "This study examined Barrett's esophagus (BE) risk factors in veterans to determine the association between risk of BE and use of oral bisphosphonates." | 1.39 | Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. ( Alsarraj, A; El-Serag, HB; Graham, DY; Kramer, JR; Lin, D; Parente, P; Ramsey, D; Rugge, M; Verstovsek, G, 2013) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Both RAL and RIS could treat osteoporosis in ORX rats; they reduced bone turnover markers and maintained BMD." | 1.39 | Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. ( El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF, 2013) |
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment." | 1.38 | The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012) |
| "Osteoporotic fractures are associated with premature mortality." | 1.37 | Osteoporosis medication and reduced mortality risk in elderly women and men. ( Bliuc, D; Center, JR; Eisman, JA; Nguyen, ND; Nguyen, TV, 2011) |
| " Although existing evidence supports a good safety profile, there is concern that chronic administration of these agents could result in severe suppression of bone turnover with increased risk of nonvertebral fractures." | 1.36 | Unusual mid-shaft fractures during long-term bisphosphonate therapy. ( Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE, 2010) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | 1.36 | Intravenous zoledronic acid: what are the indications for male osteoporosis? ( Maricic, M, 2010) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| " Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders." | 1.35 | Maximizing effectiveness of bisphosphonate therapy for osteoporosis. ( Martens, MG; Shaw, H, 2008) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| " Patients remarkably preferred therapy with a proven antifracture efficacy over a dosage frequency." | 1.35 | [Differences among bisfosfonates--specificity of risedronate (Actonel)]. ( Giljević, Z, 2008) |
| " Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise." | 1.35 | Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009) |
| "A total of 196 consecutive patients treated for distal radius fractures were included in this study." | 1.35 | Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009) |
| " Interpretations from this study are limited by assumptions of persistence based on initial drug dosing and selected refill gap length measured." | 1.35 | Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. ( Gold, DT; Safi, W; Trinh, H, 2009) |
| "A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone naïve)." | 1.35 | [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. ( Bab, S; Hayakawa, K; Hyodo, T; Iwamura, M; Kimura, M; Matsumoto, K; Okazaki, M; Satoh, T; Soh, S; Tabata, K; Tsuboi, T; Yokoyama, E, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| "Subjects were 17 postmenopausal breast cancer patients (mean age, 63." | 1.34 | Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. ( Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y, 2007) |
| "Osteoporosis is a severe complication of glucocorticoid treatment." | 1.34 | Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy." | 1.33 | Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol. ( Ando, K; Higashi, M; Ichinose, H; Kanaji, A; Nakagawa, M; Namisato, M; Sakamaki, T; Yamada, H; Yato, Y, 2005) |
| "Osteoporosis is a serious and common condition with very high associated healthcare costs." | 1.33 | A bright future for osteoporosis treatment. ( Jack, D, 2005) |
| " Although bisphosphonates are effective in treatment of osteoporosis, a strict instruction to patients on the dosage often results in their inadequate compliance with the therapy." | 1.33 | [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine]. ( Ijiri, S, 2005) |
| " The dosage regimen could be simplified by providing the two compounds in an integrated pack." | 1.33 | Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. ( Möller, G; Ringe, JD; van der Geest, SA, 2006) |
| "The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice." | 1.32 | Tolerability and compliance with risedronate in clinical practice. ( Hamilton, B; McCoy, K; Taggart, H, 2003) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| " The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat." | 1.31 | Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000) |
| " The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described." | 1.31 | Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. ( Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (1.54) | 18.2507 |
| 2000's | 199 (51.03) | 29.6817 |
| 2010's | 152 (38.97) | 24.3611 |
| 2020's | 33 (8.46) | 2.80 |
| Authors | Studies |
|---|---|
| McKenna, CE | 1 |
| Kashemirov, BA | 1 |
| Błazewska, KM | 1 |
| Mallard-Favier, I | 1 |
| Stewart, CA | 1 |
| Rojas, J | 1 |
| Lundy, MW | 1 |
| Ebetino, FH | 2 |
| Baron, RA | 1 |
| Dunford, JE | 1 |
| Kirsten, ML | 1 |
| Seabra, MC | 1 |
| Bala, JL | 1 |
| Marma, MS | 1 |
| Rogers, MJ | 1 |
| Coxon, FP | 1 |
| Thomasius, F | 5 |
| Palacios, S | 2 |
| Alam, A | 1 |
| Boolell, M | 2 |
| Vekeman, F | 2 |
| Gauthier, G | 1 |
| Waltman, N | 1 |
| Kupzyk, KA | 2 |
| Flores, LE | 1 |
| Mack, LR | 2 |
| Lappe, JM | 2 |
| Bilek, LD | 2 |
| Zhao, S | 1 |
| Zhao, W | 1 |
| Du, D | 1 |
| Zhang, C | 2 |
| Zhao, T | 1 |
| Zheng, L | 1 |
| Jin, L | 1 |
| Gu, M | 1 |
| Xu, J | 1 |
| Yang, Z | 1 |
| Hayes, KN | 2 |
| Brown, KA | 1 |
| Cheung, AM | 1 |
| Kim, SA | 1 |
| Juurlink, DN | 1 |
| Cadarette, SM | 5 |
| Shen, J | 1 |
| Ke, Z | 1 |
| Dong, S | 1 |
| Lv, M | 1 |
| Yuan, Y | 1 |
| Song, L | 1 |
| Wu, K | 1 |
| Xu, K | 1 |
| Hu, Y | 1 |
| Wells, GA | 1 |
| Hsieh, SC | 1 |
| Zheng, C | 1 |
| Peterson, J | 1 |
| Tugwell, P | 1 |
| Liu, W | 1 |
| Hsu, YH | 1 |
| Li, CC | 1 |
| Liang, FW | 1 |
| Peng, ZY | 1 |
| Chang, YF | 1 |
| Hsu, JC | 1 |
| Ou, HT | 1 |
| Wu, CH | 1 |
| Migliorini, F | 1 |
| Colarossi, G | 1 |
| Eschweiler, J | 1 |
| Oliva, F | 1 |
| Driessen, A | 1 |
| Maffulli, N | 1 |
| Sandomierski, M | 4 |
| Jakubowski, M | 4 |
| Ratajczak, M | 4 |
| Voelkel, A | 4 |
| González Macías, J | 2 |
| Olmos Martínez, JM | 1 |
| Santos, LAA | 2 |
| Lima, TB | 2 |
| de Carvalho Nunes, HR | 1 |
| Qi, X | 2 |
| Romeiro, FG | 2 |
| Li, P | 1 |
| Wu, X | 1 |
| Li, Y | 1 |
| Huang, J | 1 |
| McConnell, M | 1 |
| Shieh, A | 1 |
| Fuggle, N | 1 |
| Al-Daghri, N | 1 |
| Bock, O | 1 |
| Branco, J | 1 |
| Bruyère, O | 1 |
| Casado, E | 2 |
| Cavalier, E | 1 |
| Cortet, B | 2 |
| de Wit, M | 1 |
| Giusti, A | 1 |
| Halbout, P | 2 |
| Harvey, NC | 1 |
| Hiligsmann, M | 1 |
| Kaufman, JM | 1 |
| Kurth, A | 1 |
| Maggi, S | 2 |
| Matijevic, R | 1 |
| Minisola, S | 7 |
| Radermecker, RP | 1 |
| Tuzun, S | 1 |
| Veronese, N | 1 |
| Kanis, JA | 2 |
| Reginster, JY | 6 |
| Rizzoli, R | 1 |
| Cooper, C | 2 |
| Lee, HH | 1 |
| Choi, EY | 1 |
| Jun, HS | 1 |
| Kim, YY | 1 |
| Pokora, M | 3 |
| Zielińska, M | 3 |
| Nicolopoulos, K | 2 |
| Moshi, MR | 2 |
| Stringer, D | 2 |
| Ma, N | 2 |
| Jenal, M | 2 |
| Vreugdenburg, T | 2 |
| Eisman, JA | 4 |
| Ionescu-Ittu, R | 1 |
| Heroux, J | 1 |
| Amigues, C | 1 |
| Fresse, A | 1 |
| Roux, CH | 1 |
| Gauthier, S | 1 |
| Vieillard, MH | 1 |
| Drici, MD | 1 |
| Breuil, V | 1 |
| Xiao, Y | 2 |
| Chen, Y | 2 |
| Huang, Y | 1 |
| Sultana, N | 1 |
| Ali, A | 1 |
| Waheed, A | 1 |
| Jabi, B | 1 |
| Yaqub Khan, M | 1 |
| Mujeeb, M | 1 |
| Sultana, Y | 1 |
| Aqil, M | 1 |
| Inoue, BKN | 1 |
| Paludetto, LV | 1 |
| Monteiro, NG | 1 |
| Batista, FRS | 1 |
| Kitagawa, IL | 1 |
| da Silva, RS | 1 |
| Antoniali, C | 1 |
| Lisboa Filho, PN | 1 |
| Okamoto, R | 1 |
| Bliuc, D | 3 |
| Tran, T | 2 |
| van Geel, T | 2 |
| Adachi, JD | 7 |
| Berger, C | 2 |
| van den Bergh, J | 2 |
| Geusens, P | 8 |
| Goltzman, D | 2 |
| Hanley, DA | 2 |
| Josse, R | 1 |
| Kaiser, S | 2 |
| Kovacs, CS | 2 |
| Langsetmo, L | 2 |
| Prior, JC | 2 |
| Nguyen, TV | 3 |
| Center, JR | 3 |
| Soen, S | 4 |
| Kishimoto, H | 8 |
| Hagino, H | 5 |
| Sone, T | 1 |
| Ohishi, H | 2 |
| Fujimoto, T | 1 |
| Sasaki, E | 1 |
| Tanaka, S | 2 |
| Sugimoto, T | 4 |
| Conley, RB | 1 |
| Adib, G | 1 |
| Adler, RA | 1 |
| Åkesson, KE | 1 |
| Alexander, IM | 1 |
| Amenta, KC | 1 |
| Blank, RD | 1 |
| Brox, WT | 1 |
| Carmody, EE | 1 |
| Chapman-Novakofski, K | 1 |
| Clarke, BL | 1 |
| Cody, KM | 1 |
| Crandall, CJ | 1 |
| Dirschl, DR | 1 |
| Eagen, TJ | 1 |
| Elderkin, AL | 1 |
| Fujita, M | 1 |
| Greenspan, SL | 3 |
| Hochberg, MC | 2 |
| Javaid, M | 1 |
| Jeray, KJ | 1 |
| Kearns, AE | 2 |
| King, T | 1 |
| Koinis, TF | 1 |
| Koontz, JS | 1 |
| Kužma, M | 1 |
| Lindsey, C | 1 |
| Lorentzon, M | 1 |
| Lyritis, GP | 1 |
| Michaud, LB | 1 |
| Miciano, A | 1 |
| Morin, SN | 1 |
| Mujahid, N | 1 |
| Napoli, N | 1 |
| Olenginski, TP | 1 |
| Puzas, JE | 1 |
| Rizou, S | 1 |
| Rosen, CJ | 1 |
| Saag, K | 4 |
| Thompson, E | 1 |
| Tosi, LL | 1 |
| Tracer, H | 1 |
| Khosla, S | 1 |
| Kiel, DP | 1 |
| Iba, K | 1 |
| Takada, J | 2 |
| Sonoda, T | 1 |
| Yamashita, T | 1 |
| Park, SY | 1 |
| Kang, MI | 2 |
| Park, HM | 2 |
| Rhee, Y | 1 |
| Moon, SH | 2 |
| Yoon, HK | 2 |
| Koh, JM | 2 |
| Chang, JS | 1 |
| Kim, IJ | 1 |
| Won, YY | 1 |
| Park, YS | 1 |
| Choi, H | 1 |
| Shin, CS | 1 |
| Yoon, TR | 1 |
| Yun, SC | 1 |
| Chung, HY | 2 |
| Nunes, HRC | 1 |
| Silva, GF | 1 |
| Caramori, CA | 1 |
| Kong, F | 1 |
| Jia, B | 1 |
| Cui, P | 1 |
| Wang, D | 1 |
| Mosbahi, S | 1 |
| Oudadesse, H | 1 |
| Roiland, C | 1 |
| Lefeuvre, B | 1 |
| Slimani, L | 1 |
| Keskes, H | 1 |
| Yang, C | 1 |
| Le, G | 1 |
| Lu, C | 1 |
| Wei, R | 1 |
| Lan, W | 1 |
| Tang, J | 2 |
| Zhan, X | 1 |
| Nguyen, PV | 1 |
| Bouin, M | 1 |
| Ste-Marie, LG | 3 |
| Fujieda, Y | 1 |
| Horita, T | 1 |
| Nishimoto, N | 1 |
| Tanimura, K | 1 |
| Amasaki, Y | 1 |
| Kasahara, H | 1 |
| Furukawa, S | 1 |
| Takeda, T | 6 |
| Fukaya, S | 1 |
| Matsui, K | 1 |
| Tsutsumi, A | 2 |
| Furusaki, A | 1 |
| Sagawa, A | 1 |
| Katayama, K | 1 |
| Takeuchi, K | 1 |
| Katsumata, K | 1 |
| Kurita, T | 1 |
| Shane, P | 1 |
| Kato, M | 1 |
| Oku, K | 1 |
| Yasuda, S | 1 |
| Takahata, M | 1 |
| Iwasaki, N | 1 |
| Atsumi, T | 1 |
| Liu, Q | 1 |
| Chen, D | 1 |
| Ye, Z | 1 |
| Jin, Z | 1 |
| Ma, T | 1 |
| Huang, X | 1 |
| Kim, MY | 1 |
| Lee, K | 1 |
| Shin, HI | 1 |
| Lee, KJ | 1 |
| Jeong, D | 1 |
| Cardozo, B | 1 |
| Karatza, E | 1 |
| Karalis, V | 1 |
| Pasqualone, M | 1 |
| Andreetta, HA | 1 |
| Cortizo, MS | 1 |
| Lange, U | 2 |
| Classen, K | 1 |
| Müller-Ladner, U | 1 |
| Richter, M | 1 |
| Vico-Alonso, C | 1 |
| Maroñas-Jiménez, L | 1 |
| Lozano-Morillo, F | 1 |
| Marin, F | 5 |
| Kendler, DL | 2 |
| Russo, LA | 1 |
| Zerbini, CA | 1 |
| Body, JJ | 1 |
| Lespessailles, E | 1 |
| Bagur, A | 1 |
| Stepan, JJ | 1 |
| Lakatos, P | 1 |
| Moericke, R | 1 |
| López-Romero, P | 1 |
| Fahrleitner-Pammer, A | 2 |
| Kumagai, K | 1 |
| Harigane, K | 1 |
| Kusayama, Y | 1 |
| Tezuka, T | 1 |
| Choe, H | 1 |
| Inaba, Y | 1 |
| Saito, T | 1 |
| Soliman, ME | 1 |
| Elmowafy, E | 1 |
| Casettari, L | 1 |
| Alexander, C | 1 |
| Saag, KG | 7 |
| Wagman, RB | 1 |
| Messina, OD | 2 |
| Emkey, R | 2 |
| Chapurlat, R | 1 |
| Wang, A | 1 |
| Pannacciulli, N | 2 |
| Lems, WF | 4 |
| Tsourdi, E | 1 |
| Hofbauer, LC | 2 |
| Ren, L | 1 |
| Wang, W | 1 |
| Okazaki, R | 3 |
| Muraoka, R | 4 |
| Maehara, M | 2 |
| Inoue, D | 3 |
| Liel, Y | 1 |
| Zerbini, CAF | 1 |
| Reid, IR | 4 |
| Ishida, T | 1 |
| Yoshida, S | 3 |
| Kimura, Y | 1 |
| Fujiki, Y | 1 |
| Kotani, T | 1 |
| Takeuchi, T | 1 |
| Makino, S | 1 |
| Arawaka, S | 1 |
| Mukherjee, D | 2 |
| Srinivasan, B | 1 |
| Anbu, J | 2 |
| Azamthulla, M | 1 |
| Banala, VT | 1 |
| Ramachandra, SG | 1 |
| Randall, DR | 1 |
| Nativ-Zeltzer, N | 1 |
| Cates, DJ | 1 |
| Tinling, SP | 1 |
| Belafsky, PC | 1 |
| Oikawa, I | 1 |
| Shigematsu, T | 1 |
| Nishizawa, Y | 2 |
| Josse, RG | 2 |
| Yamamoto, K | 3 |
| Kishino, M | 1 |
| Nakamura, S | 2 |
| Tokushige, K | 1 |
| Morales-Torres, J | 1 |
| Butler, PW | 1 |
| Yin, X | 1 |
| Kameyama, N | 1 |
| Chubachi, S | 1 |
| Sasaki, M | 1 |
| Irie, H | 1 |
| Sakurai, K | 1 |
| Sayama, K | 1 |
| Nakamura, H | 1 |
| Asano, K | 1 |
| Betsuyaku, T | 1 |
| Fukunaga, K | 1 |
| Santhosh, S | 1 |
| Murahari, M | 1 |
| Teja, BV | 1 |
| Gonzalez-Rodriguez, E | 1 |
| Aubry-Rozier, B | 1 |
| Stoll, D | 1 |
| Lamy, O | 1 |
| Chattopadhyay, A | 1 |
| Sharma, SK | 1 |
| Sharma, A | 1 |
| Jain, S | 1 |
| Dhir, V | 1 |
| Ban, JK | 1 |
| Athanasiadis, G | 1 |
| Burden, AM | 1 |
| Abourehab, MAS | 1 |
| Tripto-Shkolnik, L | 1 |
| Rouach, V | 2 |
| van Boven, JF | 1 |
| de Boer, PT | 1 |
| Postma, MJ | 1 |
| Vegter, S | 1 |
| Cosman, F | 1 |
| Sahana, H | 1 |
| Khajuria, DK | 2 |
| Razdan, R | 2 |
| Mahapatra, DR | 2 |
| Bhat, MR | 1 |
| Suresh, S | 1 |
| Rao, RR | 1 |
| Mariappan, L | 1 |
| Hirschmann, S | 1 |
| Gibel, A | 1 |
| Tsvelikhovsky, I | 1 |
| Lisker, A | 1 |
| Nakamura, T | 10 |
| Nakano, T | 2 |
| Ito, M | 3 |
| Hashimoto, J | 3 |
| Tobinai, M | 3 |
| Mizunuma, H | 1 |
| Farahmand, P | 4 |
| Hawkins, F | 3 |
| Möricke, R | 2 |
| Ringe, JD | 9 |
| Glüer, CC | 2 |
| Papaioannou, N | 1 |
| Martínez, G | 2 |
| Nolla, JM | 2 |
| Niedhart, C | 2 |
| Guañabens, N | 3 |
| Nuti, R | 3 |
| Martín-Mola, E | 2 |
| Peña, J | 2 |
| Graeff, C | 2 |
| Kapetanos, G | 2 |
| Petto, H | 3 |
| Gentzel, A | 1 |
| Reisinger, A | 2 |
| Zysset, PK | 2 |
| Miyazaki, T | 1 |
| Uemura, Y | 1 |
| Kuroda, T | 1 |
| Miyakawa, N | 1 |
| Fukunaga, M | 6 |
| Ohashi, Y | 4 |
| Ohta, H | 3 |
| Mori, S | 1 |
| Hosoi, T | 2 |
| Itoi, E | 1 |
| Orimo, H | 5 |
| Shiraki, M | 6 |
| Lin, D | 1 |
| Kramer, JR | 1 |
| Ramsey, D | 1 |
| Alsarraj, A | 1 |
| Verstovsek, G | 1 |
| Rugge, M | 1 |
| Parente, P | 1 |
| Graham, DY | 1 |
| El-Serag, HB | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Damm, DD | 1 |
| Jones, DM | 1 |
| Sato, Y | 8 |
| Honda, Y | 3 |
| Iwamoto, J | 11 |
| Amano, N | 1 |
| Iolascon, G | 1 |
| Gimigliano, F | 1 |
| Orlando, V | 1 |
| Capaldo, A | 1 |
| Di Somma, C | 2 |
| Menditto, E | 1 |
| Siris, ES | 2 |
| Modi, A | 2 |
| Gandhi, S | 1 |
| Sen, S | 1 |
| Kikuta, J | 1 |
| Ishii, M | 3 |
| Horii, S | 1 |
| Banji, D | 1 |
| Banji, OJ | 1 |
| Chiluka, VL | 1 |
| Abbagoni, S | 1 |
| Shimano, RC | 1 |
| Macedo, AP | 1 |
| Falcai, MJ | 1 |
| Ervolino, E | 1 |
| Shimano, AC | 1 |
| Issa, JP | 1 |
| Pepe, J | 1 |
| Isidori, AM | 1 |
| Falciano, M | 1 |
| Iaiani, G | 1 |
| Salotti, A | 1 |
| Diacinti, D | 1 |
| Del Fiacco, R | 1 |
| Sbardella, E | 1 |
| Cipriani, C | 1 |
| Piemonte, S | 1 |
| Raimo, O | 1 |
| Biondi, P | 1 |
| Biamonte, F | 1 |
| Lenzi, A | 1 |
| Takahashi, N | 1 |
| Arai, I | 1 |
| Kayama, S | 1 |
| Ichiji, K | 1 |
| Fukuda, H | 1 |
| Handa, J | 1 |
| Konno, S | 1 |
| Ström, O | 3 |
| Landfeldt, E | 3 |
| Garellick, G | 1 |
| Benlidayi, IC | 1 |
| Ortac, EA | 1 |
| Kozanoglu, E | 1 |
| Sestak, I | 1 |
| Singh, S | 1 |
| Cuzick, J | 1 |
| Blake, GM | 1 |
| Patel, R | 1 |
| Gossiel, F | 1 |
| Coleman, R | 1 |
| Dowsett, M | 1 |
| Forbes, JF | 1 |
| Howell, A | 1 |
| Eastell, R | 3 |
| Babinets', LS | 2 |
| Semenova, IV | 2 |
| Borovyk, IO | 2 |
| Di Gregorio, S | 1 |
| Del Rio, L | 1 |
| Rodriguez-Tolra, J | 1 |
| Bonel, E | 1 |
| García, M | 1 |
| Winzenrieth, R | 1 |
| Fazil, M | 1 |
| Hassan, MQ | 1 |
| Baboota, S | 1 |
| Ali, J | 1 |
| Mellibovsky, L | 1 |
| Prieto-Alhambra, D | 1 |
| Mellibovsky, F | 1 |
| Güerri-Fernández, R | 1 |
| Nogués, X | 1 |
| Randall, C | 1 |
| Hansma, PK | 1 |
| Díez-Perez, A | 1 |
| Shah, S | 1 |
| Jeremiah, C | 1 |
| Johnson, D | 1 |
| Baker, S | 1 |
| Okano, H | 1 |
| Furuya, T | 1 |
| Urano, T | 1 |
| Hasegawa, M | 1 |
| Hirabayashi, H | 1 |
| Kumakubo, T | 1 |
| Makita, K | 1 |
| Cankaya, D | 1 |
| Tabak, Y | 1 |
| Ozturk, AM | 1 |
| Gunay, MC | 1 |
| Steve Fan, CP | 1 |
| Sajjan, S | 1 |
| Chen, LX | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Ning, GZ | 1 |
| Zhang, TS | 1 |
| Zhang, D | 1 |
| Feng, SQ | 1 |
| Cheung, MS | 1 |
| Sitjar Martínez de Sas, S | 1 |
| Aguilera de la Fuente, MT | 1 |
| Combalía Romera, J | 1 |
| Menacho Pascual, I | 1 |
| González Martínez, S | 1 |
| Altés Boronat, A | 1 |
| Yamamoto, M | 1 |
| Librizzi, MS | 1 |
| Guadalix, S | 1 |
| Martínez-Díaz Guerra, G | 1 |
| Allo, G | 1 |
| Lora, D | 1 |
| Jimenez, C | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Jandoc, R | 1 |
| Mamdani, M | 1 |
| Lévesque, LE | 1 |
| Keating, GM | 1 |
| Marques, A | 1 |
| Lourenço, Ó | 1 |
| Ortsäter, G | 1 |
| Borgström, F | 1 |
| da Silva, JA | 1 |
| Disha, C | 1 |
| Vasireddi, R | 1 |
| Rawat, P | 1 |
| Ahmad, I | 1 |
| Thomas, SC | 1 |
| Pandey, S | 1 |
| Vohora, D | 1 |
| Gupta, S | 1 |
| Ahmad, FJ | 1 |
| Talegaonkar, S | 1 |
| Veszelyné Kotán, E | 2 |
| Mészaros, Á | 2 |
| Goldshtein, I | 1 |
| Shamir-Stein, N | 1 |
| Yu, J | 2 |
| Chodick, G | 1 |
| Gong, T | 1 |
| Zhang, Y | 2 |
| Liu, X | 2 |
| Troczynski, T | 1 |
| Häfeli, UO | 1 |
| Umemura, T | 1 |
| Ando, T | 1 |
| Kamisaki, T | 2 |
| Nishikawa, M | 2 |
| Ikeda, Y | 1 |
| Takeda, K | 1 |
| Osawa, M | 2 |
| Waltman, NL | 1 |
| Cullen, DM | 1 |
| Berg, K | 1 |
| Langel, M | 1 |
| Meisinger, M | 1 |
| Portelli-Trinidad, A | 1 |
| Lang, M | 1 |
| Jiang, L | 1 |
| Shen, X | 1 |
| Wei, L | 1 |
| Zhou, Q | 2 |
| Gao, Y | 1 |
| Laius, O | 1 |
| Maasalu, K | 1 |
| Kõks, S | 1 |
| Märtson, A | 1 |
| Inderjeeth, CA | 2 |
| Inderjeeth, AJ | 1 |
| Raymond, WD | 1 |
| Mawatari, T | 1 |
| Iwamoto, Y | 1 |
| Bell, JM | 1 |
| Shields, MD | 1 |
| Watters, J | 1 |
| Hamilton, A | 1 |
| Beringer, T | 1 |
| Elliott, M | 1 |
| Quinlivan, R | 1 |
| Tirupathi, S | 1 |
| Blackwood, B | 1 |
| Nayak, S | 1 |
| Luckish, A | 1 |
| Cernes, R | 1 |
| Boaz, M | 1 |
| Gavish, D | 1 |
| Matas, Z | 1 |
| Fux, A | 1 |
| Shargorodsky, M | 1 |
| Iwasaki, T | 2 |
| Takei, K | 1 |
| Hosoda, N | 1 |
| Yokota, Y | 1 |
| Matsumoto, H | 3 |
| Yeh, JK | 2 |
| Martens, MG | 1 |
| Shaw, H | 1 |
| Ruffoni, D | 1 |
| Fratzl, P | 1 |
| Roschger, P | 1 |
| Phipps, R | 4 |
| Klaushofer, K | 1 |
| Weinkamer, R | 1 |
| Geusens, PP | 1 |
| Faber, H | 2 |
| Dorst, A | 2 |
| Lakhotia, SM | 1 |
| Tang, SY | 1 |
| Allen, MR | 2 |
| Burr, DB | 3 |
| Vashishth, D | 1 |
| Bijlsma, A | 1 |
| Blokzijl, H | 1 |
| Vecht, J | 1 |
| Lawson, MA | 1 |
| Coulton, L | 1 |
| Vanderkerken, K | 1 |
| Croucher, PI | 1 |
| Seki, A | 1 |
| Yamada, H | 3 |
| Curtis, JR | 3 |
| Westfall, AO | 3 |
| Cheng, H | 1 |
| Delzell, E | 1 |
| Verhaar, HJ | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Giljević, Z | 2 |
| Boonen, S | 4 |
| Orwoll, ES | 2 |
| Wenderoth, D | 3 |
| Stoner, KJ | 2 |
| Eusebio, R | 2 |
| Delmas, PD | 2 |
| Hines, SL | 1 |
| Mincey, BA | 1 |
| Sloan, JA | 1 |
| Thomas, SP | 1 |
| Chottiner, E | 1 |
| Loprinzi, CL | 2 |
| Carlson, MD | 1 |
| Atherton, PJ | 2 |
| Salim, M | 1 |
| Perez, EA | 1 |
| Blouin, J | 2 |
| Dragomir, A | 2 |
| Fredette, M | 1 |
| Fernandes, JC | 2 |
| Perreault, S | 2 |
| Foo, AC | 1 |
| Lai, MM | 1 |
| Glendenning, P | 1 |
| Kruk, M | 1 |
| Ralston, SH | 1 |
| Albagha, OM | 1 |
| Matsumoto, T | 2 |
| Ohbayashi, H | 1 |
| Majima, T | 3 |
| Shimatsu, A | 2 |
| Komatsu, Y | 3 |
| Satoh, N | 2 |
| Fukao, A | 3 |
| Ninomiya, K | 2 |
| Matsumura, T | 2 |
| Nakao, K | 3 |
| Katz, JN | 3 |
| Brookhart, MA | 3 |
| Stürmer, T | 2 |
| Stedman, MR | 2 |
| Levin, R | 1 |
| Solomon, DH | 2 |
| Matsumoto, Y | 1 |
| Mikuni-Takagaki, Y | 1 |
| Kozai, Y | 1 |
| Miyagawa, K | 1 |
| Naruse, K | 1 |
| Wakao, H | 1 |
| Kawamata, R | 1 |
| Kashima, I | 1 |
| Sakurai, T | 1 |
| Odvina, CV | 1 |
| Levy, S | 1 |
| Rao, S | 1 |
| Zerwekh, JE | 1 |
| Rao, DS | 1 |
| Blumentals, WA | 1 |
| Harris, ST | 1 |
| Cole, RE | 1 |
| Huang, L | 1 |
| Silverman, SL | 1 |
| Rozental, TD | 1 |
| Vazquez, MA | 1 |
| Chacko, AT | 1 |
| Ayogu, N | 1 |
| Bouxsein, ML | 1 |
| Gennari, L | 1 |
| Bilezikian, JP | 2 |
| Reid, DM | 7 |
| Devogelaer, JP | 7 |
| Roux, C | 3 |
| Lau, CS | 3 |
| Papanastasiou, P | 3 |
| Ferreira, A | 1 |
| Hartl, F | 1 |
| Fashola, T | 1 |
| Mesenbrink, P | 1 |
| Sambrook, PN | 3 |
| Zhong, ZM | 1 |
| Chen, JT | 1 |
| Uyar, Y | 1 |
| Baytur, Y | 1 |
| Inceboz, U | 1 |
| Demir, BC | 1 |
| Gumuser, G | 1 |
| Ozbilgin, K | 1 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Ye, Y | 1 |
| Hu, SJ | 1 |
| Northfelt, DW | 1 |
| Dueck, AC | 1 |
| Dakhil, SR | 1 |
| Rowland, KM | 1 |
| Fuloria, J | 1 |
| Flynn, PJ | 1 |
| Dentchev, T | 1 |
| Kriel, MH | 1 |
| Tobias, JH | 1 |
| Creed, TJ | 1 |
| Lockett, M | 1 |
| Linehan, J | 1 |
| Bell, A | 1 |
| Przemioslo, R | 1 |
| Smithson, JE | 1 |
| Brooklyn, TN | 1 |
| Fraser, WD | 1 |
| Probert, CS | 1 |
| Gold, DT | 1 |
| Trinh, H | 1 |
| Safi, W | 1 |
| Kwak, HB | 1 |
| Kim, JY | 1 |
| Kim, KJ | 1 |
| Choi, MK | 1 |
| Kim, JJ | 1 |
| Kim, KM | 1 |
| Shin, YI | 1 |
| Lee, MS | 1 |
| Kim, HS | 1 |
| Kim, JW | 1 |
| Chun, CH | 1 |
| Cho, HJ | 1 |
| Hong, GY | 1 |
| Juhng, SK | 1 |
| Yoon, KH | 1 |
| Park, BH | 1 |
| Bae, JM | 1 |
| Han, JK | 1 |
| Oh, J | 1 |
| Keel, C | 1 |
| Kraenzlin, ME | 1 |
| Kraenzlin, CA | 1 |
| Müller, B | 1 |
| Meier, C | 1 |
| Asano, S | 1 |
| Suzuki, A | 1 |
| Itoh, M | 2 |
| Willey, JS | 1 |
| Livingston, EW | 1 |
| Robbins, ME | 1 |
| Bourland, JD | 1 |
| Tirado-Lee, L | 1 |
| Smith-Sielicki, H | 1 |
| Bateman, TA | 1 |
| Chevalier, Y | 1 |
| Quek, E | 1 |
| Borah, B | 1 |
| Gross, G | 1 |
| Stewart, J | 1 |
| Lang, T | 1 |
| Zysset, P | 1 |
| Epstein, S | 2 |
| Jeglitsch, M | 1 |
| McCloskey, E | 1 |
| Feher, A | 1 |
| Koivunemi, A | 1 |
| Koivunemi, M | 1 |
| Fuchs, RK | 1 |
| Phipps, RJ | 2 |
| Reinwald, S | 1 |
| Bahlous, A | 1 |
| Bouzid, K | 1 |
| Sahli, H | 1 |
| Sallami, S | 1 |
| Abdelmoula, J | 1 |
| Bolland, MJ | 1 |
| Grey, AB | 1 |
| Gamble, GD | 1 |
| Gates, BJ | 1 |
| Sonnett, TE | 1 |
| Duvall, CA | 1 |
| Dobbins, EK | 1 |
| Berto, P | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Yamazaki, Y | 1 |
| Shiraki, Y | 1 |
| Tsugawa, N | 1 |
| Okano, T | 1 |
| Maricic, M | 3 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Taxel, P | 1 |
| Dowsett, R | 1 |
| Richter, L | 1 |
| Fall, P | 1 |
| Klepinger, A | 1 |
| Albertsen, P | 1 |
| Girgis, CM | 1 |
| Sher, D | 1 |
| Seibel, MJ | 2 |
| Takakuwa, M | 2 |
| Konishi, M | 1 |
| Itabashi, K | 2 |
| Leonida, A | 1 |
| Vescovi, P | 1 |
| Baldoni, M | 1 |
| Rossi, G | 1 |
| Lauritano, D | 1 |
| Aapro, MS | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Takei, T | 1 |
| Itabashi, M | 1 |
| Tsukada, M | 1 |
| Sugiura, H | 1 |
| Moriyama, T | 1 |
| Kojima, C | 1 |
| Shiohira, S | 1 |
| Shimizu, A | 1 |
| Karasawa, K | 1 |
| Amemiya, N | 1 |
| Kawanishi, K | 1 |
| Ogawa, T | 1 |
| Uchida, K | 1 |
| Tsuchiya, K | 1 |
| Nitta, K | 1 |
| Orita, S | 1 |
| Ohtori, S | 1 |
| Koshi, T | 1 |
| Yamashita, M | 1 |
| Yamauchi, K | 1 |
| Inoue, G | 1 |
| Suzuki, M | 1 |
| Eguchi, Y | 1 |
| Kamoda, H | 1 |
| Arai, G | 1 |
| Ishikawa, T | 1 |
| Miyagi, M | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Takaso, M | 1 |
| Aoki, Y | 1 |
| Toyone, T | 1 |
| Takahashi, K | 1 |
| Bachmeyer, C | 1 |
| Gauthier, M | 1 |
| Nguyen, ND | 1 |
| Smith, EM | 1 |
| Fujita, Y | 1 |
| Watanabe, K | 1 |
| Uchikanbori, S | 1 |
| Maki, K | 1 |
| Izumi, K | 1 |
| Mizokami, A | 1 |
| Sugimoto, K | 1 |
| Narimoto, K | 1 |
| Kitagawa, Y | 1 |
| Koh, E | 1 |
| Namiki, M | 1 |
| Fujita, T | 1 |
| Ohue, M | 1 |
| Nakajima, M | 1 |
| Fujii, Y | 1 |
| Miyauchi, A | 1 |
| Takagi, Y | 1 |
| Geoffroy, V | 1 |
| Paschalis, EP | 1 |
| Libouban, H | 2 |
| Blouin, S | 1 |
| Ostertag, A | 1 |
| Chappard, D | 2 |
| Cros, M | 1 |
| de Vernejoul, MC | 1 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Chin, SO | 1 |
| Yoon, BK | 1 |
| Chung, YS | 1 |
| Lee, JH | 1 |
| Lee, SH | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Peris, P | 1 |
| Torra, M | 1 |
| Olivares, V | 1 |
| Reyes, R | 1 |
| Monegal, A | 1 |
| Martínez-Ferrer, A | 1 |
| Umeno, K | 1 |
| Hayashida, N | 1 |
| Hannon, RA | 1 |
| Rodriguez-Moreno, J | 1 |
| Sawicki, A | 1 |
| Ott, SM | 1 |
| Martin, KE | 1 |
| Campbell, HE | 1 |
| Abarca, J | 1 |
| White, TJ | 1 |
| Yurci, A | 1 |
| Kalkan, AO | 1 |
| Ozbakir, O | 1 |
| Karaman, A | 1 |
| Torun, E | 1 |
| Kula, M | 1 |
| Baskol, M | 1 |
| Gursoy, S | 1 |
| Yucesoy, M | 1 |
| Bayram, F | 1 |
| Bucci-Rechtweg, C | 3 |
| Su, G | 3 |
| Nam, SH | 1 |
| Jeong, JH | 1 |
| Che, X | 1 |
| Lim, KE | 1 |
| Nam, H | 1 |
| Park, JS | 1 |
| Choi, JY | 1 |
| Nonoda, Y | 1 |
| Soo, I | 1 |
| Siffledeen, J | 1 |
| Siminoski, K | 1 |
| McQueen, B | 1 |
| Fedorak, RN | 1 |
| Pazianas, M | 1 |
| Abrahamsen, B | 1 |
| Wang, Y | 1 |
| Russell, RG | 2 |
| Markopoulos, C | 1 |
| Tzoracoleftherakis, E | 1 |
| Koukouras, D | 1 |
| Venizelos, B | 1 |
| Zobolas, V | 1 |
| Misitzis, J | 1 |
| Xepapadakis, G | 1 |
| Gogas, H | 1 |
| Davey, DA | 1 |
| Angthong, C | 1 |
| Angthong, W | 1 |
| Kim, TY | 1 |
| Ha, YC | 1 |
| Kang, BJ | 1 |
| Lee, YK | 1 |
| Koo, KH | 1 |
| Lorenc, RS | 1 |
| Khedr, NF | 1 |
| El-Ashmawy, NE | 1 |
| El-Bahrawy, HA | 1 |
| Haggag, AA | 1 |
| El-Abd, EE | 1 |
| Hemmati, I | 1 |
| Wade, J | 1 |
| Kelsall, J | 1 |
| Yamaguchi, H | 1 |
| Iinuma, N | 1 |
| Hayakawa, Y | 1 |
| Suzuki, H | 1 |
| Iwayama, S | 1 |
| Walker, MD | 1 |
| Cusano, NE | 1 |
| Sliney, J | 1 |
| Romano, M | 1 |
| McMahon, DJ | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Itoh, S | 1 |
| Sekino, Y | 1 |
| Shinomiya, K | 1 |
| Takeda, S | 1 |
| Ferko, NC | 1 |
| Borisova, N | 1 |
| Airia, P | 1 |
| Grima, DT | 1 |
| Thompson, MF | 1 |
| Choo, R | 1 |
| Lukka, H | 1 |
| Cheung, P | 1 |
| Corbett, T | 1 |
| Briones-Urbina, R | 1 |
| Vieth, R | 1 |
| Ehrlich, L | 1 |
| Kiss, A | 1 |
| Danjoux, C | 1 |
| Papaioannu, N | 1 |
| Sanz, B | 1 |
| Sambrook, P | 1 |
| Goemaere, S | 1 |
| Ish-Shalom, S | 1 |
| Collette, J | 1 |
| Erben, RG | 1 |
| Mosekilde, L | 2 |
| Thomsen, JS | 2 |
| Weber, K | 1 |
| Stahr, K | 1 |
| Leyshon, A | 1 |
| Smith, SY | 1 |
| Välimäki, MJ | 1 |
| Collier, J | 1 |
| Srivastava, M | 1 |
| Deal, C | 1 |
| Kushida, K | 3 |
| Taketani, Y | 2 |
| Minaguchi, H | 2 |
| Inoue, T | 2 |
| Morita, R | 2 |
| Morii, H | 2 |
| Baranauskaite, A | 2 |
| Savickiene, A | 1 |
| Minne, HW | 1 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Miller, PD | 1 |
| Bartl, R | 2 |
| Sohen, S | 1 |
| Hamilton, B | 1 |
| McCoy, K | 1 |
| Taggart, H | 2 |
| Prestwood, KM | 2 |
| Raisz, LG | 2 |
| Traut, V | 1 |
| Larocque, D | 1 |
| Tauchmanovà, L | 1 |
| Selleri, C | 1 |
| Esposito, M | 1 |
| Orio, F | 1 |
| Bifulco, G | 1 |
| Palomba, S | 1 |
| Lombardi, G | 1 |
| Rotoli, B | 1 |
| Colao, A | 1 |
| Ettinger, MP | 2 |
| Taha, EA | 1 |
| Youssef, NF | 1 |
| Miller, L | 1 |
| Grynpas, M | 1 |
| Li, J | 1 |
| Boyde, A | 1 |
| Mashiba, T | 1 |
| Hirano, T | 1 |
| Johnston, CC | 1 |
| Cohen, SB | 1 |
| Naganathan, V | 1 |
| Barton, I | 2 |
| Grauer, A | 1 |
| Ogura, Y | 2 |
| Gonsho, A | 2 |
| Cyong, JC | 2 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Ott, S | 1 |
| Marx, J | 1 |
| Vanderschueren, D | 1 |
| Kanaji, A | 2 |
| Higashi, M | 2 |
| Namisato, M | 2 |
| Ando, K | 2 |
| Nakagawa, M | 1 |
| Yato, Y | 1 |
| Ichinose, H | 1 |
| Sakamaki, T | 1 |
| Li, CY | 1 |
| Price, C | 1 |
| Delisser, K | 1 |
| Nasser, P | 1 |
| Laudier, D | 1 |
| Clement, M | 1 |
| Jepsen, KJ | 1 |
| Schaffler, MB | 1 |
| Illgner, U | 1 |
| Teichmann, J | 1 |
| Schleenbecker, H | 1 |
| Sebba, AI | 1 |
| Bonnick, SL | 1 |
| Kagan, R | 1 |
| Thompson, DE | 1 |
| Skalky, CS | 1 |
| Chen, E | 1 |
| de Papp, AE | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Pande, I | 2 |
| Hosking, DJ | 3 |
| Laan, RF | 3 |
| Barton, IP | 2 |
| Watts, NB | 2 |
| Arai, T | 1 |
| Inoue, Y | 1 |
| Hayashi, S | 1 |
| Yamamoto, S | 1 |
| Sakatani, M | 1 |
| McClung, M | 3 |
| O'Brien, FJ | 1 |
| Brennan, O | 1 |
| Kennedy, OD | 1 |
| Lee, TC | 1 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Heaney, RP | 1 |
| Valent, DJ | 1 |
| Jack, D | 1 |
| Fujii, N | 1 |
| Hamano, T | 1 |
| Isaka, Y | 1 |
| Ito, T | 1 |
| Imai, E | 1 |
| Ijiri, S | 2 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Orcel, P | 1 |
| Dogru, T | 1 |
| Sonmez, A | 1 |
| Tasci, I | 1 |
| Genc, H | 1 |
| Henderson, S | 1 |
| Hoffman, N | 1 |
| Prince, R | 1 |
| Dobnig, H | 1 |
| Viereck, V | 1 |
| Obermayer-Pietsch, B | 1 |
| Allison, J | 1 |
| Freeman, A | 2 |
| Kovac, SH | 1 |
| Doi, K | 1 |
| Takagi, C | 1 |
| Shigemoto, M | 1 |
| Morimoto, T | 1 |
| Corners, J | 1 |
| Naunton, M | 1 |
| Troen, BR | 1 |
| Allison, JJ | 1 |
| Neumaier, J | 1 |
| Downey, TW | 1 |
| Foltz, SH | 1 |
| Boccuzzi, SJ | 1 |
| Omar, MA | 1 |
| Kahler, KH | 1 |
| Buckland-Wright, JC | 1 |
| Messent, EA | 1 |
| Bingham, CO | 1 |
| Ward, RJ | 1 |
| Tonkin, C | 1 |
| Nishio, M | 1 |
| van der Geest, SA | 1 |
| Möller, G | 1 |
| Itabashi, A | 1 |
| Nawata, H | 1 |
| Takaoka, K | 1 |
| Adami, S | 4 |
| Isaia, G | 1 |
| Luisetto, G | 1 |
| Sinigaglia, L | 1 |
| Gentilella, R | 1 |
| Agnusdei, D | 1 |
| Iori, N | 1 |
| Cruse, LM | 1 |
| Valeriano, J | 1 |
| Vasey, FB | 1 |
| Carter, JD | 1 |
| Suzuki, Y | 2 |
| Bobba, RS | 1 |
| Beattie, K | 1 |
| Parkinson, B | 1 |
| Kumbhare, D | 1 |
| Lambrinoudaki, I | 1 |
| Christodoulakos, G | 1 |
| Botsis, D | 1 |
| Avorn, J | 1 |
| Finkelstein, JS | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Sato, S | 1 |
| Khosa, AD | 1 |
| Nayyar, MS | 1 |
| Beirne, JC | 1 |
| Yamasaki, S | 1 |
| Masuhara, K | 1 |
| Yamaguchi, K | 1 |
| Nakai, T | 1 |
| Fuji, T | 1 |
| Seino, Y | 1 |
| Vlak, T | 1 |
| Kamatari, M | 1 |
| Koto, S | 1 |
| Ozawa, N | 1 |
| Urao, C | 1 |
| Akasaka, E | 1 |
| Yanagimoto, K | 1 |
| Sakota, K | 1 |
| Yamada, S | 1 |
| Takagi, H | 1 |
| Tsuchiya, H | 1 |
| Nakajima, T | 1 |
| Ochiai, H | 1 |
| Ichimura, A | 1 |
| Iwata, H | 1 |
| Toriyama, T | 1 |
| Yonehara, Y | 1 |
| Iwamoto, I | 1 |
| Kosha, S | 1 |
| Rai, Y | 1 |
| Sagara, Y | 1 |
| Douchi, T | 1 |
| Christodoulakos, GE | 1 |
| Mellström, D | 1 |
| Nickelsen, T | 1 |
| Pavo, I | 1 |
| Nakayama, H | 1 |
| Dalle Carbonare, L | 1 |
| Bertoldo, F | 1 |
| Valenti, MT | 1 |
| Zordan, S | 1 |
| Sella, S | 1 |
| Fassina, A | 1 |
| Turco, G | 1 |
| Realdi, G | 1 |
| Lo Cascio, V | 1 |
| Giannini, S | 1 |
| Ishizaka, K | 1 |
| Machida, T | 1 |
| Kobayashi, S | 1 |
| Kanbe, N | 1 |
| Kitahara, S | 1 |
| Yoshida, K | 1 |
| Mok, CC | 1 |
| Tong, KH | 1 |
| To, CH | 1 |
| Siu, YP | 1 |
| Ma, KM | 1 |
| Bobba, R | 1 |
| Ding, H | 1 |
| Koinuma, N | 1 |
| Stevenson, M | 1 |
| Monma, Y | 1 |
| Narusawa, K | 1 |
| Sosa Henríquez, M | 1 |
| Díaz Curiel, M | 1 |
| Díez Pérez, A | 1 |
| Gómez Alonso, C | 1 |
| Farrerons Minguella, J | 1 |
| Filgueira Rubio, J | 1 |
| Mellibovsky Saidler, L | 1 |
| Nogués Solán, X | 1 |
| Hernández Hernández, D | 1 |
| Morishita, M | 1 |
| Nagashima, M | 1 |
| Wauke, K | 1 |
| Takahashi, H | 1 |
| Takenouchi, K | 1 |
| Kimura, M | 1 |
| Satoh, T | 1 |
| Okazaki, M | 1 |
| Tabata, K | 1 |
| Tsuboi, T | 1 |
| Hyodo, T | 1 |
| Yokoyama, E | 1 |
| Matsumoto, K | 1 |
| Soh, S | 1 |
| Iwamura, M | 1 |
| Hayakawa, K | 1 |
| Bab, S | 1 |
| Gärtner, R | 1 |
| Moride, Y | 1 |
| Geller, JL | 1 |
| Hu, B | 2 |
| Reed, S | 1 |
| Mirocha, J | 1 |
| Adams, JS | 1 |
| Licata, AA | 2 |
| Ma, YF | 1 |
| Pan, Z | 1 |
| Jee, WS | 1 |
| Lin, CH | 1 |
| Liang, HH | 1 |
| Chen, H | 1 |
| Pun, S | 1 |
| Li, XJ | 1 |
| Li, QN | 1 |
| Liang, NC | 1 |
| Huang, LF | 1 |
| Wu, T | 1 |
| Mo, LE | 1 |
| Dunlop, MB | 1 |
| Lane, NE | 1 |
| Hamdy, RC | 1 |
| Kessenich, CR | 1 |
| Hughes, RA | 2 |
| Sacco-Gibson, NA | 1 |
| Wenderoth, DH | 1 |
| Eusebio, RA | 1 |
| Hunziker, J | 1 |
| Wronski, TJ | 1 |
| Miller, SC | 1 |
| Peel, NF | 1 |
| Chines, AA | 3 |
| Bax, DE | 1 |
| Sacco-Gibson, N | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Leder, BZ | 1 |
| Kronenberg, HM | 1 |
| Wallach, S | 1 |
| Cohen, S | 1 |
| Doherty, SM | 1 |
| Rosen, C | 1 |
| Brown, J | 1 |
| Baran, DT | 1 |
| Mackey, MS | 1 |
| Papapoulos, SE | 1 |
| Crandall, C | 1 |
| Chapurlat, RD | 1 |
| Cefalu, CA | 1 |
| Kauffman, RP | 1 |
| Overton, TH | 1 |
| Shiflett, M | 1 |
| Jennings, JC | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| McClung, B | 1 |
| Peters, ML | 1 |
| Leonard, M | 1 |
| Bolognese, MA | 1 |
| Lindsay, R | 1 |
| Mulder, H | 1 |
| Roberts, A | 1 |
| Zippel, H | 1 |
| Ernst, TF | 1 |
| Stevens, KP | 1 |
| Dougherty, JA | 1 |
| Bannwarth, B | 1 |
| Moreau, MF | 1 |
| Legrand, E | 1 |
| Baslé, MF | 1 |
| Audran, M | 1 |
| Roll, KT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures[NCT01709110] | Phase 4 | 1,366 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial[NCT04034199] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-08-15 | Not yet recruiting | ||
| A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals[NCT01575873] | Phase 3 | 795 participants (Actual) | Interventional | 2012-03-28 | Completed | ||
| International Breast Cancer Intervention Study[NCT00078832] | Phase 3 | 3,864 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study[NCT03401619] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2017-09-21 | Active, not recruiting | |||
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study[NCT05265988] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-10-29 | Recruiting | ||
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma[NCT00054418] | Phase 3 | 216 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis[NCT00100620] | Phase 3 | 802 participants | Interventional | 2004-06-30 | Completed | ||
| Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study[NCT00043069] | Phase 3 | 71 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study[NCT00619957] | Phase 3 | 285 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis[NCT01611571] | Phase 3 | 31 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men[NCT00503399] | Phase 3 | 92 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| The Pharmacokinetics and Pharmacodynamics Study of Intravenous Zoledronic Acid in Chinese Subjects With Low Bone Mass or Osteoporosis: a Randomized Placebo-controlled Trail[NCT04719650] | Phase 4 | 64 participants (Anticipated) | Interventional | 2021-10-31 | Not yet recruiting | ||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
A major non-vertebral fracture is a fracture at any of the following non-vertebral sites hip, radius, humerus, ribs, pelvis, tibia and femur. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 18 |
| Risedronate | 31 |
Vertebrae were graded as moderate (SQ2), or severe (SQ3) fractures, based on ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 through L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 26 |
| Risedronate | 63 |
(NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 2 |
| Risedronate | 12 |
"The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation.~A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures identified by QM were confirmed using SQ: if the vertebral body also had an increase of one or more severity grade, it was considered an incident vertebral fracture." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 28 |
| Risedronate | 64 |
A non-vertebral fracture is a fracture at any of the following non-vertebral sites: clavicle, scapula, ribs, sternum, sacrum, coccyx, humerus, radius, ulna, carpus, pelvis, hip, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object were not considered fragility fractures but traumatic fractures. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 25 |
| Risedronate | 38 |
"A clinical vertebral fracture was defined as a new or worsening vertebral fracture, confirmed by radiography, that was associated with signs and symptoms highly suggestive of a vertebral fracture.~All non-vertebral fractures that occurred and were diagnosed between visits required the confirmation by the site investigators after evaluating the original x-ray film(s), the radiology or surgical report. For clinical vertebral fractures, the final confirmation of the diagnosis required the centralized evaluation by a trained, independent reader." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 30 |
| Risedronate | 61 |
Traumatic fractures were considered if resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 40 |
| Risedronate | 57 |
Worsening of a pre-existing fracture was considered if the decrease in vertebral height was at least one severity grade in the semi-quantitative assessment, confirmed by a trained central reader, where vertebrae were graded as normal (SQ0) or as with mild (SQ1), moderate (SQ2), or severe (SQ3) fractures, defined as ~20 to 25% (mild), ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 to L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 31 |
| Risedronate | 69 |
Participants rated the worst back pain during the 24 hours preceding the visit at baseline and each post-baseline visit. An 11-point numerical back pain rating scale (rated from 0 = no back pain to 10 = worst possible back pain) was used. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 4.5 | 3.4 |
| Teriparatide | 4.5 | 3.4 |
(NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | Centimeter (cm) (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 155.0 | 154.5 |
| Teriparatide | 154.7 | 154.3 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.59 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.62 | 0.68 |
| Teriparatide | 0.59 | 0.65 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United States (US) cross walk algorithm, with scores ranging from -0.11 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.72 | 0.76 |
| Teriparatide | 0.70 | 0.74 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 0.8 |
| Denosumab: Glucocorticoid-initiating | 3.8 |
| Risedronate: Glucocorticoid-continuing | 2.3 |
| Denosumab: Glucocorticoid-continuing | 4.4 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 0.8 |
| Denosumab: Glucocorticoid-initiating | 3.8 |
| Risedronate: Glucocorticoid-continuing | 2.3 |
| Denosumab: Glucocorticoid-continuing | 4.4 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 1.7 |
| Denosumab: Glucocorticoid-initiating | 6.2 |
| Risedronate: Glucocorticoid-continuing | 3.2 |
| Denosumab: Glucocorticoid-continuing | 6.4 |
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 0.2 |
| Denosumab: Glucocorticoid-initiating | 1.7 |
| Risedronate: Glucocorticoid-continuing | 0.6 |
| Denosumab: Glucocorticoid-continuing | 2.1 |
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | -0.0 |
| Denosumab: Glucocorticoid-initiating | 3.1 |
| Risedronate: Glucocorticoid-continuing | 0.5 |
| Denosumab: Glucocorticoid-continuing | 2.9 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | millimeters (Least Squares Mean) |
|---|---|
| Placebo | -2.39 |
| Risedronate | -2.68 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | millimeters (Least Squares Mean) |
|---|---|
| Placebo | -0.77 |
| Risedronate | -0.92 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | millimeters (Least Squares Mean) |
|---|---|
| Placebo | -2.66 |
| Risedronate | -3.13 |
Kaplan-Meier Cumulative Incidence, fractures / 100 patients / year (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Fractures / 100 patients / year (Number) |
|---|---|
| Placebo | 3.4 |
| Risedronate | 2.7 |
Kaplan-Meier Cumulative Incidence, fractures / 100 patients / 2 years (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Fractures / 100 patients / 2 years (Number) |
|---|---|
| Placebo | 7.7 |
| Risedronate | 4.9 |
(NCT00619957)
Timeframe: Baseline to Month 3
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | -8.89 |
| Risedronate | -24.53 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.99 |
| Risedronate | -25.27 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -7.11 |
| Risedronate | -29.51 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 2.95 |
| Risedronate | -25.20 |
(NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -8.68 |
| Risedronate | -29.78 |
(NCT00619957)
Timeframe: Baseline to Month 3
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -14.56 |
| Risedronate | -58.16 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 6.39 |
| Risedronate | -38.76 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -19.12 |
| Risedronate | -61.46 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 9.28 |
| Risedronate | -37.27 |
(NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -13.72 |
| Risedronate | -58.44 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.53 |
| Risedronate | 1.59 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.62 |
| Risedronate | 1.49 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.42 |
| Risedronate | 1.65 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Baseline femoral neck values measured on Lunar instruments will be normalized to Hologic reference. Hologic Reference BMD = (0.836 x BMD[lunar]) - 0.008 (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.48 |
| Risedronate | 0.98 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.57 |
| Risedronate | 2.73 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.81 |
| Risedronate | 1.89 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.52 |
| Risedronate | 2.83 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.67 |
| Risedronate | 1.24 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.42 |
| Risedronate | 4.60 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Mean of 2 scans performed. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.40 |
| Risedronate | 5.98 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading.DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.03 |
| Risedronate | 3.60 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Site will perform at screening to determine if scan should be forwarded to central facility for analysis. Mean of 2 scans performed read by central lab to determine entry qualification. Results standardized (sBMD): Hologic sBMD = 1000 x (BMD x 1.0755), Lunar sBMD = 1000 x (BMD x 0.9522). (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 1.22 |
| Risedronate | 5.75 |
(NCT00619957)
Timeframe: Baseline to Month 3
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -17.41 |
| Risedronate | -33.28 |
(NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -20.45 |
| Risedronate | -36.82 |
(NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -16.46 |
| Risedronate | -38.42 |
(NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -22.27 |
| Risedronate | -37.38 |
(NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | -7.98 |
| Risedronate | -29.97 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to 24 Months/Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.24 |
| Risedronate | 1.71 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to Month 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.74 |
| Risedronate | 1.38 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines. Scans will be forwarded to central facility for analysis. Mean of 2 scans performed will be utilized. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.06 |
| Risedronate | 1.76 |
DXA (dual energy x-ray absorptiometry) assayed on Lunar or Hologic machines and forwarded to central laboratory for reading. Results standardized (sBMD): Hologic sBMD = 1000 x (1.008 x BMD + 0.006), Lunar sBMD = 1000 x (0.979 x BMD - 0.031). (NCT00619957)
Timeframe: Baseline to Month 6
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Placebo | 0.76 |
| Risedronate | 1.16 |
responder = positive change (>0) in lumbar spine BMD from Baseline to Month 24 (NCT00619957)
Timeframe: Baseline to Month 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 60.3 |
| Risedronate | 89.5 |
Change in the Femoral Neck BMD at 18 month (NCT01611571)
Timeframe: 18 months
| Intervention | % change in TH BMD (Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 8.45 |
| Active Risedronte Placebo Teriparatide | 0.5 |
| Placebo Risedronate Active Teriparatide | 3.89 |
change in 1/3 radius of forearm bone density as measured by DXA (NCT01611571)
Timeframe: baseline and 18 months
| Intervention | % change in 1/3 Radius BMD (Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 1.6 |
| Active Risedronte Placebo Teriparatide | 0.11 |
| Placebo Risedronate Active Teriparatide | 0.02 |
change in hip bone density measured by DXA (NCT01611571)
Timeframe: baseline and 18 months
| Intervention | % change in TH BMD (Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 3.86 |
| Active Risedronte Placebo Teriparatide | 0.82 |
| Placebo Risedronate Active Teriparatide | 0.29 |
change in spine bone density at 18 months measured by DXA 18 and 24 months (NCT01611571)
Timeframe: 18 months
| Intervention | % change in LS BMD (Least Squares Mean) |
|---|---|
| Active Risedronate Active Teriparatide | 6.95 |
| Active Risedronte Placebo Teriparatide | 3.76 |
| Placebo Risedronate Active Teriparatide | 5.68 |
counting the total new morphometric vertebral fractures as determined by x-ray from baseline through end of study (NCT01611571)
Timeframe: baseline through 18 months
| Intervention | vertebral fracture (Number) |
|---|---|
| Active Risedronate Active Teriparatide | 1 |
| Active Risedronte Placebo Teriparatide | 1 |
| Placebo Risedronate Active Teriparatide | 0 |
Least Squares (LS) Means were adjusted for age, baseline propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) |
|---|---|
| Teriparatide | 4.31 |
| Risedronate | 2.52 |
Least Squares (LS) Means were adjusted for age, baseline serum aminoterminal propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 18 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) |
|---|---|
| Teriparatide | 12.28 |
| Risedronate | 2.94 |
Anterior bending and axial torsion were measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | Newton/millimeter/radian (N/mm/rad) (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anterior bending stiffness at 6 months | Anterior bending stiffness at 18 months | Axial torsion stiffness at 6 months | Axial torsion stiffness at 18 months | Anterior bending strength at 6 months | Anterior bending strength at 18 months | Axial torsion strength at 6 months | Axial torsion strength at 18 months | |
| Risedronate | 415705.0 | 233283.0 | 77830.7 | 56639.3 | 8827.2 | 4822.0 | 3664.0 | 2545.8 |
| Teriparatide | 664969.0 | 1209225.0 | 142902.9 | 279392.8 | 12490.9 | 26046.4 | 6127.7 | 14181.3 |
Dual x-ray absorptiometry (DXA) techniques validated this measurement at skeletal sites that are at risk of osteoporotic fracture, such as lumbar spine, femoral neck, and hip. (NCT00503399)
Timeframe: Baseline, 18 months
| Intervention | grams per square centimeter (g/cm^2) (Mean) | ||
|---|---|---|---|
| Lumbar spine (n=38; n=39) | Hip (n=38; n=37) | Femoral neck (n=38; n=37) | |
| Risedronate | 0.037 | 0.007 | -0.007 |
| Teriparatide | 0.068 | 0.014 | 0.014 |
Axial compression was measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated the strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | Newton per millimeter (N/mm) (Least Squares Mean) | |||
|---|---|---|---|---|
| Axial compression stiffness at 6 months | Axial compression stiffness at 18 months | Axial compression strength at 6 months | Axial compression strength at 18 months | |
| Risedronate | 407.6 | 363.7 | 313.6 | 209.4 |
| Teriparatide | 890.7 | 1973.9 | 580.7 | 1287.5 |
Three-dimensional (3-D) microstructure variables of T12 were assessed by HR-QCT. In contrast with regular QCT that assessed 3 millimeter (mm) slide thickness, HR-QCT used segmentation of 1 single vertebra with approximately 100 consecutive slides reconstructed at 300-400 micrometer (µm) slice increments covering the complete vertebral body. Least Squares (LS) Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months
| Intervention | milligram per cubic centimeter (mg/cm^3) (Least Squares Mean) | |||
|---|---|---|---|---|
| Integral BMD at 6 months | Integral BMD at 18 months | Trabecular BMD at 6 months | Trabecular BMD at 18 months | |
| Risedronate | -1.91 | 0.68 | -0.87 | 0.22 |
| Teriparatide | -0.42 | 10.72 | -0.70 | 9.53 |
P1NP was used as a serum biochemical marker of collagen synthesis, reflecting the formation of new osteoid. (NCT00503399)
Timeframe: Baseline, 3 months, 6 months, 18 months
| Intervention | micrograms per deciliter (μg/dL) (Least Squares Mean) | ||
|---|---|---|---|
| P1NP at 3 months | P1NP at 6 months | P1NP at 18 months | |
| Risedronate | -16.09 | -16.50 | -15.58 |
| Teriparatide | 27.33 | 52.55 | 28.48 |
β-CTx was used as a biochemical marker of bone turnover/resorption, reflecting collagen breakdown of the bone matrix. (NCT00503399)
Timeframe: 3, 6, 18 months
| Intervention | nanograms per deciliter (ng/dL) (Least Squares Mean) | ||
|---|---|---|---|
| β-CTx at 3 months | β-CTx at 6 months | β-CTx at 18 months | |
| Risedronate | -0.15 | -0.14 | -0.11 |
| Teriparatide | 0.12 | 0.25 | 0.03 |
Summary tables of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module. Fractures that occurred during the study were collected separately as an additional safety variable. The number of participants experiencing hypercalcemia was summarized for each treatment arm. Hypercalcemia was defined as a serum calcium level corrected for albumin of >2.7 millimole per liter (mmol/L) (10.8 milligram per deciliter [mg/dL]). (NCT00503399)
Timeframe: Baseline up to 18 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Serious Adverse Events (SAEs) | Other Non-serious AEs | Fractures | Hypercalcemia | |
| Risedronate | 22 | 30 | 5 | 0 |
| Teriparatide | 13 | 22 | 0 | 0 |
99 reviews available for risedronic acid and Age-Related Osteoporosis
| Article | Year |
|---|---|
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle A | 2022 |
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Netw | 2022 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Aged; Female; Hip Fractures; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractu | 2022 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zole | 2022 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Et | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapa | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; M | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Hum | 2022 |
Novel formulations of oral bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Horm | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Huma | 2023 |
Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials.
Topics: Bone Density; Female; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; | 2020 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-C | 2020 |
Effect of risedronate on femoral periprosthetic bone loss following total hip replacement: A systematic review and meta-analysis.
Topics: Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Femur; Humans; Osteo | 2018 |
[Dynamics of bone resorption analyzed by intravital imaging].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; | 2013 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservati | 2014 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans | 2015 |
Drugs Used in Paediatric Bone and Calcium Disorders.
Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitoni | 2015 |
Ibandronate: A Review in Japanese Patients with Osteoporosis.
Topics: Administration, Intravenous; Administration, Oral; Bone Density; Bone Density Conservation Agents; D | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Topics: Adult; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III | 2017 |
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; | 2017 |
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Denosumab; Humans; Male; Osteoporosis; Os | 2017 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations | 2008 |
[Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Fractures, | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Admini | 2009 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometall | 2009 |
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Follow | 2009 |
[Risedronate for treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spont | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosph | 2009 |
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2010 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceut | 2009 |
Challenges in clinical patient management.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etid | 2010 |
[Dementia and fracture].
Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism | 2010 |
Treatments for osteoporosis in people with a disability.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Disabled Persons; Etidronic Acid; Hu | 2011 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
Risedronate-associated scleritis: a case report and review of the literature.
Topics: Adrenal Cortex Hormones; Aged; Brain; China; Diphosphonates; Etidronic Acid; Female; Humans; Inflamm | 2012 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Osteoporosis: diagnosis and treatment of vertebral fractures].
Topics: Age Factors; Aged; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Middle A | 2002 |
Editorial: greater risk, greater benefit--true or false?
Topics: Calcium Channel Blockers; Etidronic Acid; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk | 2003 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; | 2002 |
[Risedronate].
Topics: Aged; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
Prevention and treatment of osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Calcium; Dietary Supplements; Estrogen Replacement Therapy; Etidronic | 2002 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Os | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
An update on bisphosphonates.
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Hum | 2004 |
[New guideline for the treatment of osteoporosis].
Topics: Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medic | 2004 |
[Risedronate treatment for osteoporosis].
Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fra | 2004 |
[VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study].
Topics: Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteo | 2004 |
[Combination therapy of bisphosphonate and estrogen for osteoporosis].
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Fem | 2004 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Algorithms; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteop | 2004 |
Fracture protection in osteoporosis with risedronate.
Topics: Aged; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Ag | 2004 |
[Bone quality in treatment with raroxifene ].
Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C | 2005 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu | 2005 |
Microcracks in cortical bone: how do they affect bone biology?
Topics: Animals; Bone and Bones; Bone Matrix; Bone Remodeling; Calcium Channel Blockers; Etidronic Acid; Fra | 2005 |
Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Huma | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; | 2006 |
[Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Hydroxych | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandroni | 2006 |
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporo | 2007 |
[Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postme | 2006 |
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteop | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fractures, | 2007 |
[Bisphosphonates for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Diphosphonates; Etidronic Acid; Ev | 2007 |
[Evidence of risedronate for treatment of osteoporosis].
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Evidenc | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Conf | 2008 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supp | 1999 |
Risedronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Adrenal Cortex Hormones; Aged; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporos | 2000 |
Prevention and treatment of osteoporosis.
Topics: Accidental Falls; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium Chan | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Oste | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen R | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F | 2001 |
Risedronate: clinical usage.
Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei | 2001 |
Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.
Topics: Adolescent; Calcium Channel Blockers; Calcium, Dietary; Diagnosis, Differential; Etidronic Acid; Fem | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid | 2001 |
Review of risedronate in the treatment of osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Pos | 2001 |
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clinical Trials, Phase III as | 2002 |
Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Mal | 2002 |
[Risedronate: clinical usage].
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; H | 2002 |
Bone quality: getting closer to a definition.
Topics: Animals; Bone Density; Etidronic Acid; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Risedron | 2002 |
82 trials available for risedronic acid and Age-Related Osteoporosis
| Article | Year |
|---|---|
Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2022 |
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial.
Topics: Bone Density; Bone Density Conservation Agents; Esophageal and Gastric Varices; Esophagitis; Gastroi | 2022 |
Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis.
Topics: Aged; Alendronate; Bone Density; Disease-Free Survival; Female; Humans; Male; Middle Aged; Osteoporo | 2019 |
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dou | 2020 |
Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; | 2019 |
Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Aged; Calcium; Esophageal and Gastric Varices; Female; Follow-Up Stud | 2019 |
Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Fe | 2021 |
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Topics: Aged; Double-Blind Method; Female; Humans; Osteoporosis; Postmenopause; Risedronic Acid; Risk Factor | 2018 |
Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; B | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Creatini | 2019 |
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Colla | 2019 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; E | 2013 |
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Cons | 2013 |
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Glome | 2014 |
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation | 2013 |
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response Relati | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Topics: Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Demography; Diphosphonates; Drug Administr | 2016 |
[Comparative analysis of programs of complete correction osteogenic in patients with chronic pancreatitis].
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; M | 2014 |
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Collagen Type I; Creatinine; | 2016 |
Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Comorbidity; Diabetes Mellitus; Double- | 2016 |
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Diphosphonates; Female; Femoral Neck Fractures; | 2017 |
Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.
Topics: Aged; Arteries; Biomarkers; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; D | 2008 |
Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Anticonvulsants; Benzodiazepines; Biomarke | 2008 |
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Aci | 2009 |
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neo | 2009 |
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Topics: Aged; Asian People; Back Pain; Body Height; Bone Density; Bone Density Conservation Agents; Bone Rem | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density | 2009 |
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Double-Blind | 2010 |
Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Drug Administration S | 2010 |
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2010 |
Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Topics: Aged; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female | 2010 |
Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Clinical Protocols; Co | 2009 |
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Epidemiologic | 2010 |
Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Hydroxycholec | 2010 |
Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antineoplastic Age | 2011 |
Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Female; Humans; Knee | 2011 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalci | 2011 |
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bone Density; Bone Density Conservation Agents; Etidroni | 2011 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen | 2011 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone De | 2012 |
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosph | 2012 |
Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Ch | 2012 |
Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2012 |
Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic A | 2012 |
Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Topics: Bone Density; Bone Density Conservation Agents; Demography; Double-Blind Method; Etidronic Acid; Fem | 2012 |
Combination therapy with risedronate and teriparatide in male osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; | 2013 |
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle | 2013 |
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Cons | 2013 |
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Euro | 2013 |
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2013 |
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Topics: Adult; Aged; Biomarkers; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid | 2002 |
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calci | 2003 |
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
Topics: Administration, Oral; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administr | 2003 |
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteopo | 2004 |
Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
Topics: Administration, Oral; Adult; Area Under Curve; Calcium Channel Blockers; Dose-Response Relationship, | 2004 |
Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.
Topics: Administration, Oral; Adult; Calcium Channel Blockers; Cross-Over Studies; Drug Administration Sched | 2004 |
Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Bone and Bones; C-Reactive Protein; Cross-Linking Reage | 2004 |
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Do | 2004 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Double-Blind Method | 2005 |
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Fractures, | 2006 |
A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; | 2006 |
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remo | 2006 |
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Di | 2006 |
A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Disease Progression; Dose-Response Relationship, Drug | 2007 |
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Bli | 2006 |
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Adminis | 2006 |
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bo | 2007 |
Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation | 2007 |
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Bone Density Conservation Agents; Etidroni | 2007 |
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Topics: Adipose Tissue; Adult; Aged; Anti-Inflammatory Agents; Body Mass Index; Bone Density; Bone Density C | 2008 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; C | 2008 |
Efficacy of risedronate in Japanese male patients with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conse | 2008 |
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density; Consumer Product | 2000 |
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Channel Blockers; Double-Bl | 2000 |
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Ca | 2000 |
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2001 |
209 other studies available for risedronic acid and Age-Related Osteoporosis
| Article | Year |
|---|---|
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Surv | 2010 |
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Canada; Cohort Studies; Female; Hu | 2022 |
Zeolitic Imidazolate Framework‑8 (ZIF-8) modified titanium alloy for controlled release of drugs for osteoporosis.
Topics: Alloys; Delayed-Action Preparations; Humans; Osteoporosis; Risedronic Acid; Spectroscopy, Fourier Tr | 2022 |
Osteoclast and Sclerostin Expression in Osteocytes in the Femoral Head with Risedronate Therapy in Patients with Hip Fractures: A Retrospective Comparative Study.
Topics: Aged; Bone Density; Female; Femur Head; Hip Fractures; Humans; Osteoclasts; Osteocytes; Osteoporosis | 2022 |
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile.
Topics: Calcium; Humans; Magnesium; Osteoporosis; Pharmaceutical Preparations; Risedronic Acid; Zeolites; Zi | 2023 |
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile.
Topics: Calcium; Humans; Magnesium; Osteoporosis; Pharmaceutical Preparations; Risedronic Acid; Zeolites; Zi | 2023 |
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile.
Topics: Calcium; Humans; Magnesium; Osteoporosis; Pharmaceutical Preparations; Risedronic Acid; Zeolites; Zi | 2023 |
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile.
Topics: Calcium; Humans; Magnesium; Osteoporosis; Pharmaceutical Preparations; Risedronic Acid; Zeolites; Zi | 2023 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic | 2023 |
Dissolving microneedle transdermal patch loaded with Risedronate sodium and Ursolic acid bipartite nanotransfersomes to combat osteoporosis: Optimization, characterization, in vitro and ex vivo assessment.
Topics: Drug Delivery Systems; Humans; Osteoporosis; Risedronic Acid; Transdermal Patch; Ursolic Acid | 2023 |
Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis.
Topics: Animals; Bone Density; Female; Humans; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Risedronic Aci | 2023 |
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Topics: Alendronate; Bone Density Conservation Agents; Consensus; Diphosphonates; Humans; Osteoporosis; Oste | 2020 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Col | 2020 |
Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Drug Delivery Systems; Drug Therapy | 2019 |
Risedronate Effects on the In Vivo Bioactive Glass Behavior: Nuclear Magnetic Resonance and Histopathological Studies.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Durapatite; Female; Glass; Magnetic Resonan | 2019 |
Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients.
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hu | 2021 |
Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I | 2021 |
Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels.
Topics: Administration, Oral; Cross-Over Studies; Humans; Models, Biological; Osteoporosis; Renal Insufficie | 2021 |
Risedronate transdermal delivery system based on a fumaric copolymer for therapy of osteoporosis.
Topics: Administration, Cutaneous; Calorimetry, Differential Scanning; Drug Delivery Systems; Humans; Osteop | 2017 |
Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fol | 2017 |
Management of Corticosteroid-Induced Osteoporosis: A Practical Approach for the Dermatologist.
Topics: Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium | 2018 |
Star-shaped poly(oligoethylene glycol) copolymer-based gels: Thermo-responsive behaviour and bioapplicability for risedronate intranasal delivery.
Topics: Administration, Intranasal; Animals; Bone and Bones; Bone Density Conservation Agents; Delayed-Actio | 2018 |
Denosumab: a new treatment option for glucocorticoid-induced osteoporosis.
Topics: Bone Density Conservation Agents; Denosumab; Double-Blind Method; Glucocorticoids; Humans; Osteoporo | 2018 |
Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Female; Humans; Japan; Logistic Models; Male; | 2019 |
Teriparatide vs risedronate for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Teriparatide vs risedronate for osteoporosis - Authors' reply.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Denosumab for glucocorticoid-induced osteoporosis.
Topics: Bone Density Conservation Agents; Denosumab; Double-Blind Method; Glucocorticoids; Humans; Osteoporo | 2018 |
Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
Topics: Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Fem | 2018 |
Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film.
Topics: Animals; Bone and Bones; Chitosan; Disease Models, Animal; Drug Compounding; Female; Methylprednisol | 2018 |
Decreased intramuscular calcium hydroxyapatite implant resorption in a murine model of osteoporosis.
Topics: Animals; Disease Models, Animal; Drug Implants; Durapatite; Female; Injections; Muscle, Skeletal; Os | 2018 |
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Diphosphonates; Etidronic Acid; Female; | 2019 |
Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Gastrointesti | 2019 |
Predictive and modifying factors of bone mineral density decline in patients with COPD.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Female; Humans | 2019 |
Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Chitosan; Drug Carriers; Female; Nanopartic | 2019 |
Reply.
Topics: Denosumab; Double-Blind Method; Glucocorticoids; Humans; Osteoporosis; Risedronic Acid | 2019 |
Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Double-Blind Method; Glucocorticoids; H | 2019 |
Where Does Denosumab Stand in the Treatment of Glucocorticoid-Induced Osteoporosis? Comment on the Article by Saag et al.
Topics: Bone Density Conservation Agents; Denosumab; Double-Blind Method; Glucocorticoids; Humans; Osteoporo | 2019 |
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2019 |
Hyaluronic Acid Modified Risedronate and Teriparatide Co-loaded Nanocarriers for Improved Osteogenic Differentiation of Osteoblasts for the Treatment of Osteoporosis.
Topics: 3T3 Cells; Animals; Cell Differentiation; Drug Carriers; Hyaluronic Acid; Mice; Nanoparticles; Osteo | 2019 |
A dramatic increase in bone mineral density, enhanced osteoblast activity and malignancy.
Topics: Absorptiometry, Photon; Aged, 80 and over; Bone Density; Humans; Lumbar Vertebrae; Male; Osteoblasts | 2020 |
Persistence with osteoporosis medication among newly-treated osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Huma | 2013 |
Is there a role for combination therapy for osteoporosis?
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid; Terip | 2013 |
Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
Topics: Adsorption; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Chemistry, Pharmaceutica | 2013 |
Late-onset psychosis and risedronate treatment for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Menopause; Middle Aged; Osteop | 2015 |
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Topics: Aged; Alendronate; Barrett Esophagus; Bone Density Conservation Agents; Case-Control Studies; Diphos | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Dis | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidr | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; | 2014 |
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats.
Topics: Animals; Bone Density; Bone Resorption; Collagen; Etidronic Acid; Femur; Free Radical Scavengers; Gl | 2014 |
Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Et | 2014 |
Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chol | 2014 |
Four-year follow-up of pregnancy-associated osteoporosis: a case report.
Topics: Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Low Back Pain; Osteoporosis; Pr | 2014 |
Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorb | 2015 |
Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Neurofibromatos | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
[Osteodeficiency in chronic pancreatitis: ways of correction].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Bone Density Conservation | 2014 |
Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS).
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; | 2015 |
Biodegradable intranasal nanoparticulate drug delivery system of risedronate sodium for osteoporosis.
Topics: Administration, Intranasal; Drug Carriers; Drug Delivery Systems; Humans; Lactic Acid; Nanoparticles | 2016 |
Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2015 |
Risedronate as an intra-abdominal sepsis mimic: a case report.
Topics: Abdominal Abscess; Aged; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Ac | 2015 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, | 2015 |
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Ga | 2015 |
[PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis].
Topics: Aged; Bone Density Conservation Agents; Female; Humans; Medication Adherence; Osteoporosis; Product | 2016 |
Trabecular bone score in patients with liver transplants after 1 year of risedronate treatment.
Topics: Aged; Bone Density Conservation Agents; Female; Humans; Liver Transplantation; Male; Middle Aged; Os | 2016 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
Urban-rural differences in the uptake of new oral bisphosphonate formulations.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Diphosph | 2016 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analys | 2016 |
Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Density Conservation Agents; Calcium; Creatinine | 2016 |
Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment.
Topics: Animals; Biological Availability; Bone and Bones; Bone Density Conservation Agents; Cell Line; Cell | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; | 2016 |
Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Sectional Studies; Databases, Factual; Fe | 2016 |
Osteogenic and anti-osteoporotic effects of risedronate-added calcium phosphate silicate cement.
Topics: Animals; Bone Cements; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphates; Female | 2016 |
Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.
Topics: Aged; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Drug Administra | 2017 |
Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Exercise; Female; Humans; Mid | 2016 |
Effects of bisphosphonates on mandibular condyle of ovariectomized osteoporotic rats using micro-ct and histomorphometric analysis.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Mandibular Cond | 2017 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; D | 2016 |
Medication selection and patient compliance in the clinical management of osteoporosis.
Topics: Australia; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Patient Compliance; Ph | 2016 |
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; | 2008 |
Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Computer Simulation; Etidronic Acid; Female; Humans; | 2008 |
Osteoporosis in men.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Osteoporosis; | 2008 |
Monthly risedronate (Actonel) for postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Fees, Pharmaceutical | 2008 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone | 2009 |
[Severe oesophagus injury as a complication during treatment with risedronic acid].
Topics: Aged; Bone Density Conservation Agents; Esophagus; Etidronic Acid; Gastrointestinal Motility; Humans | 2008 |
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model | 2008 |
Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Syne | 2008 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2009 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
[Differences among bisfosfonates--specificity of risedronate (Actonel)].
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Fractures, Spontaneo | 2008 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; F | 2009 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic A | 2009 |
[Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis].
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservatio | 2009 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Drug Administration Schedule; Drug Evaluatio | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidroni | 2010 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fem | 2009 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo | 2009 |
Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocortico | 2009 |
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clo | 2009 |
Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
Topics: Apolipoproteins; Arteries; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; Et | 2009 |
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Etidronic Acid; Female; | 2009 |
Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Cell Su | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2009 |
Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Etidronic Acid; Female; Mice; Mice, Inbre | 2010 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonate | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Hum | 2010 |
Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Fractures, | 2011 |
Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dental Arch; Dental Prosthesis, I | 2012 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.
Topics: Afferent Pathways; Animals; Back Pain; Bone Density Conservation Agents; Cells, Cultured; Disease Mo | 2010 |
How to prevent glucocorticoid-induced osteoporosis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Humans; Organometallic Compounds; | 2010 |
Osteoporosis medication and reduced mortality risk in elderly women and men.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; | 2011 |
Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats.
Topics: Anatomy, Cross-Sectional; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Etid | 2011 |
Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alph | 2011 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Multiple vertebral compression fractures associated with post partum osteoporosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fractures, C | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Remodeling; Case-Control Studies; Diphosphonates; | 2011 |
Effect of stopping risedronate after long-term treatment on bone turnover.
Topics: Aged; Bone Density; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur; Humans; Lumbar V | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diph | 2011 |
Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model.
Topics: Administration, Topical; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fe | 2012 |
The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drugs, Gener | 2012 |
Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agen | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; F | 2011 |
Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Topics: Administration, Oral; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation A | 2013 |
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity; | 2012 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; E | 2012 |
Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Density; Calcitriol; Etidronic Acid; Female; Ost | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibilit | 2001 |
Commentary on: Bone mineral density and fracture prevalence in long-term kidney graft recipients.
Topics: Bone Density; Etidronic Acid; Fractures, Bone; Humans; Kidney Transplantation; Osteoporosis; Prevale | 2002 |
Once-a-week risedronate (actonel).
Topics: Administration, Oral; Digestive System; Diphosphonates; Dose-Response Relationship, Drug; Drug Admin | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Tolerability and compliance with risedronate in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointe | 2003 |
[Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
Topics: Alendronate; Budgets; Drug Costs; Etidronic Acid; Evidence-Based Medicine; Germany; Humans; National | 2003 |
Show us the numbers.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Drug Industry; Etidronic Acid; Humans; Incidence | 2003 |
Spectrophotometric determination of some drugs for osteoporosis.
Topics: Alendronate; Etidronic Acid; Osteoporosis; Risedronic Acid; Spectrophotometry | 2003 |
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Calcification, Physiologic; Carbonates; Collage | 2003 |
[Consistent therapeutic success in osteoporosis].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2004 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic | 2004 |
New treatments for brittle bones.
Topics: Alendronate; Animals; Bone Density; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
[Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].
Topics: Age Factors; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Hip F | 2004 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou | 2004 |
Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Femur; Hip Fractures; Humans; Hydroxycholecal | 2005 |
Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Diphosphonates; Dogs; Drug Resistance; Etidronic | 2005 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; | 2004 |
Risedronate induced BOOP complicated with sarcoidosis.
Topics: Aged; Calcium Channel Blockers; Cryptogenic Organizing Pneumonia; Etidronic Acid; Female; Humans; Mu | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2005 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Hospitalization-related bone loss and the protective effect of risedronate.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur | 2006 |
A bright future for osteoporosis treatment.
Topics: Adrenergic beta-Antagonists; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2005 |
[Risedronate: a possible treatment for extraosseous calcification].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; CREST Syndrome; Etidronic | 2005 |
[Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middl | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
Symptomatic hypocalcemia due to oral risedronate therapy.
Topics: Adult; Bone Density Conservation Agents; Celiac Disease; Etidronic Acid; Humans; Hypocalcemia; Male; | 2005 |
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Topics: Alendronate; Databases as Topic; Diphosphonates; Drug Prescriptions; Drug Utilization; Etidronic Aci | 2006 |
Is the increase in osteoporosis prevention a result of the audit?
Topics: Adrenal Cortex Hormones; Alendronate; Bone Density Conservation Agents; Calcium; Clinical Trials as | 2006 |
Osteoporosis in older people: a tale of two studies (and three treatments).
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hum | 2006 |
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Glucocorticoids; | 2006 |
[Only bone densitometry answers this question. How stable are your patients' bones?].
Topics: Absorptiometry, Photon; Aged; Bone Density; Diphosphonates; Etidronic Acid; Femoral Neck Fractures; | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Ma | 2006 |
Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium, Dietary; Dietary Supplements; Dr | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation | 2006 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidron | 2007 |
[Men also need bone protection].
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2006 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Logistic Model | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis | 2007 |
[Osteoporosis treatment: choices and options].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Aci | 2007 |
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Mo | 2007 |
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Bone; Humans; Jap | 2008 |
[Patient's preference for the daily and weekly bisphosphonate--evaluation from questionnaire of osteoporosis patients].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administratio | 2008 |
[Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].
Topics: Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Risedronic Acid | 2008 |
[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].
Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fracture | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidr | 2008 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Cons | 2008 |
Intermittent on/off prostaglandin E2 and risedronate are equally anabolic as daily PGE2 alone treatment in cortical bone of ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcium Channel Blockers; Dinoprostone; Drug | 1997 |
Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Remodeling; Disease Models, Animal; Drug Administration Schedule; Etid | 1999 |
Risedronic acid. NE 58095, risedronate sodium, Actonel.
Topics: Aged; Animals; Drugs, Investigational; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Os | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis | 1999 |
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates | 2000 |
[A new bisphosphonate. A vertebral body fracture seldom remains alone].
Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal | 2000 |
New developments in osteoporosis treatment.
Topics: Alendronate; Anticholesteremic Agents; Drug Administration Schedule; Etidronic Acid; Humans; Osteopo | 2000 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; | 2000 |
Hip fractures: do preventive drugs work for all?
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Os | 2001 |
Osteoporosis in men.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid | 2001 |
[Fluorides and bisphosphonates in the treatment of osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Topics: Aged; Calcium Channel Blockers; Cortisone; Costs and Cost Analysis; Double-Blind Method; Etidronic A | 2002 |
[When osteoporosis first manifests itself. Without therapy the next fracture threatens].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2002 |
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone and Bones; Bone Density; Climacteric; Disease Mod | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; | 2002 |